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ABSTRACT
Myocardial infarction remains an important cause of death and disability
in Scotland. Although initial mortality is largely a consequence of
arrhythmias, after the first few hours mortality and morbidity is closely
related to the extent of myocardial damage and subsequent ventricular
dilatation. This thesis discusses means of reducing left ventricular
dysfunction after myocardial infarction.
The first two sections describe a placebo controlled double blind clinical
trial of oral therapy with captopril or isosorbide mononitrate initiated
early after myocardial infarction and continued for 28 days. Left
ventricular function and volume as assessed by echocardiography,
radionuclide ventriculography or magnetic resonance imaging was similar
in the placebo and vasodilator groups at 5 weeks. Even the placebo
group showed a trend to a decrease in ventricular diameter. In contrast
to many similar studies most of these patients (88%) received
thrombolysis, perhaps resulting in a population with little tendency to
ventricular dilatation.
Clinical outcome (death, cardiogenic shock) was significantly better in
the captopril group, suggesting this agent may have a role for high risk
patients (possibly those with persisting coronary occlusion). However
there was no evidence that vasodilator therapy reduced infarct size as
quantified by tomographic radionuclide imaging. In addition the acute
inflammatory response, as reflected by measures of neutrophil activation
and free radical lipid attack, was not modified by vasodilator therapy.
The last two sections focus on coronary artery reperfusion. A detailed
3
study of 17 patients with myocardial infarction found streptokinase
therapy caused complement and neutrophil activation, particularly in
those that did not reperfuse. This inflammatory activation may lead to a
detrimental increase in infarct size. The pattern of complement
activation was consistent with plasmin mediated proteolytic activation
rather than an antigen-antibody reaction.
The last section describes a retrospective review of cases of ventricular
septal rupture post infarction and demonstrates that thrombolysis does
not modify the presentation of this complication. Rupture almost always
occurred in the context of failed reperfusion. This data refutes the
theory that rupture is a consequence of harmful intramyocardial
haemorrhage secondary to reperfusion.
In conclusion, left ventricular dilatation post myocardial infarction is
decreased by ensuring patency of the infarct related coronary artery.
Thrombolysis readily achieves this in the majority of cases, but it is
associated with potentially deleterious acute inflammatory activation.
Thrombolysis has not modified the presentation of septal rupture; it is
still seen in those that fail to reperfuse. In high risk individuals
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Myocardial infarction remains the commonest cause of death in middle
aged men in Scotland. In addition the Scottish mortality rate from
myocardial infarction is one of the highest national rates in the world
(Uemura and Pisa, 1988). For example, in 1989 the mortality rate from
myocardial infarction for men aged 55-64 years was 559.6 per 100,000
in Scotland compared to a rate of 348.3 per 100,000 in England and
Wales (World Health Statistics, 1990) and only 112.6 per 100,000 in
France (World Health Statistics, 1991). The size of the problem in
Scotland can be appreciated when one considers that the mortality rate
from lung cancer for Scottish men in the same age group is only 247.3
per 100,000 (World Health Statistics, 1990).
Over the last 15 years much has been learnt about the pathological
processes that occur during and after myocardial infarction. This
improvement in understanding has led to important changes in
treatment and outcome of this very common condition.
PATHOLOGY
The clinical syndrome of myocardial infarction was first described by
Obrastrow and Straschenko (1910). Two years later, in 1912, Herrick
reported his description of the 'clinical features of sudden obstruction of
the coronary arteries'. In both these papers coronary artery thrombosis
was clearly stated as the cause of the clinical syndrome. In the mid
20th century there was debate as to whether coronary thrombosis was
the cause or the result of myocardial infarction (Hackel et al, 1969). As
recently as 1980 Silver et al wrote of the lack of importance of coronary
thrombosis in myocardial infarction. In their autopsy series of 100
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patients with myocardial infarction only 45% had occlusive coronary
artery thrombi. However, in the same year DeWood et al (1980)
reported their findings from coronary angiography which confirmed the
importance of thrombotic occlusion of a coronary artery in the early
hours after myocardial infarction. Less than 4 hours after the onset of
pain, 97.3% of patients had a total or subtotal occlusion of the relevant
coronary artery. Recently percutaneous angioscopy has allowed
visualisation of such thrombi in vivo. Greyish-white platelet rich thrombi
are seen in patients with unstable angina, whereas occlusive reddish
thrombi predominantly comprising fibrin and erythrocytes are found in
subjects with myocardial infarction (Mizuno et al, 1992).
Coronary thrombosis is initiated by rupture of an atherosclerotic plaque
(Falk, 1983; Davies and Thomas, 1985). The deeper the fissure the
more likely the thrombotic process will result in coronary artery
occlusion (Davies and Thomas, 1985). However, it is not a prerequisite
that an atherosclerotic plaque should be large and causing a severe
stenosis prior to rupture. In an angiographic study two thirds of the
plaques that had progressed to thrombosis had not even been
haemodynamically significant (less than 60% stenosis) prior to the
event. Similarly in a prospective angiographic study the majority of
lesions (85%) that caused clinical myocardial infarcts were not severe
(less than 75% stenosis) at their initial assessment (Webster et al,
1990).
Once the artery is occluded by the superimposed thrombus, myocardial
necrosis ensues. Thankfully this does not occur instantly following
cessation of blood flow or techniques like coronary angioplasty would
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not be possible without causing infarction. Animal studies suggest that
myocyte injury progresses from an initial reversible state to irreversibility
and necrosis (Reimer and Jennings, 1979). These workers demonstrated
that in the dog the wavefront of necrosis starts in the endocardium after
20 minutes of occlusion and spreads towards the epicardium as the
duration of occlusion is prolonged. In this animal the degree of necrosis
has reached its maximum ('transmural infarction') within 6 hours of
arresting flow.
Even if an artery remains occluded permanently, myocardial necrosis
does not normally involve the entire thickness of the ventricular wall. A
rim of epicardium remains viable. These cells are preserved by epicardial
collateral flow which in the dog varies between 1 % and 41 % of the
preocclusion blood flow (Reimer and Jennings, 1979). The magnitude of
this collateral flow is a major determinant of the extent of myocardial
necrosis. Indeed this accounts for the difference in infarct size between
different experimental models. In the dog, which has a well developed
collateral blood supply, coronary occlusion produces a transmural infarct
in only 54% of cases (Eaton et al, 1981). In contrast the same
procedure in the rat results in transmural damage in 95% of animals
because of the poorer collateral blood flow in this species (Hochman and
Bulkley, 1982).
The greatly enhanced collateral flow seen in some patients with chronic
ischaemic heart disease can result in significant prolongation of the time
course of cell death such that myocardial salvage is possible beyond 6
hours (Jennings and Reimer, 1983). This protective effect of collateral
blood flow is illustrated by the observation that a third of patients with
non Q wave infarction have persisting occlusion of the offending
coronary artery, but with retrograde perfusion of that artery by collateral
vessels (DeWood et al, 1986). Indeed it is possible for an artery to
occlude without causing infarction if collateral flow is sufficiently
developed (Webster et al, 1990).
Coronary thrombosis is a dynamic process with some patent vessels
progressing to total occlusion and others reopening as a result of
spontaneous fibrinolysis (DeWood et al, 1980; DeWood et al, 1986).
Over the first 24 hours after the onset of chest pain there is a decrease
in the proportion of patients with coronary artery occlusion (DeWood et
al, 1980). During this time 35% of patients will spontaneously
reperfuse the occluded artery (DeWood et al, 1980). Other studies have
shown increasing arterial patency rates over the weeks following
infarction. Angiographic patency was seen in 41 % of infarct related
arteries 1 week after infarction (National Heart Foundation of Australia
Coronary Thrombolysis Group, 1988) and after 3 weeks the percentage
patent had risen to around 60% (White et al, 1987a; O'Rourke et al,
1988). The dynamic nature of the process of coronary thrombosis is
emphasised by human pathological studies. In an autopsy series of
patients with unstable angina Falk et al (1985) report that coronary
thrombi have a layered structure comprising material of different ages.
In addition there is evidence of previous fragmentation with microemboli
in the distal circulation and microinfarcts in the same distribution.
THROMBOLYTIC THERAPY
Understanding of the importance of thrombosis in precipitating coronary
artery occlusion has resulted in therapy designed to remove the
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thrombus. The fibrinolytic system is the body's natural mechanism for
clot lysis and depends on the enzyme plasmin attacking insoluble fibrin
matrix. Active plasmin can also be generated by pharmacological
manipulation with agents such as streptokinase, anistreplase and tissue
plasminogen activator (reviewed by Marder and Sherry, 1988).
The first reported use of streptokinase in patients with acute myocardial
infarction was in a small study by Fletcher et al in 1959. Many reports
followed but the individual results were inconclusive. They tended to
randomise relatively few patients and used low dose regimes which
continued for many hours. The data from 33 of these studies was
subjected to a meta-analysis which found that fibrinolytic therapy
reduced the risk of death by 22% (Yusuf et al, 1985).
The beneficial action of thrombolytic therapy was later borne out in the
large multicentre trials employing high dose but short duration
treatment. In the GISSI (Gruppo Italiano per lo studio della
Streptochinasi nell'infarto miocardico) study (1 986) 11,712 patients
were randomised to either streptokinase 1.5MU over 1 hour or no
thrombolytic therapy. The 21 day mortality rate was reduced by 18% in
the thrombolysed patients. Similar findings were reported by the ISIS-2
(Second International Study in Infarct Survival) trial (1988) which
employed the same thrombolysis protocol (25% reduction in the odds of
death in the first 5 weeks). Anistreplase, anisoylated plasminogen
streptokinase activator complex, was studied in 1004 patients in the
AIMS (APSAC Intervention Mortality Study) trial (1988) and reduced the
30 day mortality by 47%. The mortality rate 1 month after infarction
was decreased by 26% in those treated with recombinant tissue-type
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plasminogen activator in the ASSET (Anglo-Scandinavian Study of Early
Thrombolysis) study (Wilcox et al, 1988).
As a result of these and other studies thrombolytic therapy has become
the standard treatment for acute myocardial infarction. Two of these
large studies indicated that the benefit of treatment was greater when it
was given earlier after the onset of pain (ISIS2, 1988; GISSI, 1986) and
this has lead to efforts to ensure that patients are treated as soon as
possible after presentation. Angiographic studies have confirmed that
thrombolytic therapy does increase the proportion of patients with
patent infarct related arteries both acutely and in the longer term after
infarction (White et al, 1987a; National Heart Foundation of Australia
Coronary Thrombolysis Group, 1988; O'Rourke et al, 1988).
REPERFUSION INJURY
Lysis of an occluding coronary thrombus (both spontaneous and drug
induced) results in reperfusion of ischaemic myocardium. Kloner et al
(1974a) have described the morphological changes that occur rapidly
following reperfusion in the canine myocardium. Within 10 minutes of
reperfusion the cells which have suffered "irreversible injury" swell and
exhibit contraction band necrosis with large granular mitochondrial
densities. There has been considerable debate concerning the possibility
that such reperfusion might cause myocardial damage ("reperfusion
injury"). The main body of evidence that supports the existence of
reperfusion injury has been derived from animal models that have
demonstrated that a variety of pharmacological interventions can
decrease the extent of myocyte injury caused by a period of ischaemia
and reperfusion. For instance Romson et al (1983) described an
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experiment using an open chest dog model of infarction that involved
reperfusion after coronary occlusion for 90 minutes. Infarct size was
reduced by a mean of 43% in those dogs depleted of circulating
neutrophils by pretreatment with neutrophil antiserum.
As yet there is no direct evidence from clinical studies to indicate that
reperfusion injury exists in man. Indeed reperfusion induced by
thrombolytic therapy lowers mortality after myocardial infarction
(GISS1, 1986; ISIS-2, 1988) and if achieved early after the onset of
chest pain, at least some of the benefit emanates from a decrease in
infarct size (White et al, 1987a; O'Rourke et al, 1988). Although the
beneficial consequences of reperfusion are clear, this does not exclude
the possibility that adjuvant therapy to limit reperfusion injury might
bring even greater reductions in infarct size. There are a number of
different mechanisms that have been proposed as mediators of myocyte
injury in the context of myocardial infarction and reperfusion. These are
reviewed in the next section and the potential for adjuvant therapy to
decrease such injury is discussed where relevant.
MEDIATORS OF INJURY
a) Oxygen free radicals
These molecules have an unpaired electron and are highly reactive and
cytotoxic. These chemical species can modify important cellular
molecules including lipids, proteins and nucleic acids. They can both
cause injury and be produced as a result of injury. Oxygen can react to
produce several such molecules.






02- + Fe3+ —-> Fe2+ + 02
3. H202 + Fe2+ -—> Fe3+ + OH" + OH-
(hydroxyl radical)
This chain of reactions leads to the production of the highly reactive
hydroxyl radical which is probably the most important of the oxygen
radicals in causing biological effects (Pyror, 1986). Studies with isolated
rabbit interventricular septa have shown that perfusion with hydroxyl
radical generating media causes extensive morphological changes to
both myocytes and endothelial cells, and decreases muscle function
(Burton et al, 1984). Superoxide dismutase, which scavenges the
superoxide radical and prevents the formation of the hydroxyl radical,
protected against these changes when it was added to the perfusate.
There are several potential sources of free radicals in the context of
myocardial infarction.
1) Xanthine oxidase system (McCord, 1985)
As a result of ischaemia ATP is degraded through a number of
intermediates to hypoxanthine. In addition xanthine
dehydrogenase is converted to xanthine oxidase by calcium
dependent proteases. Hypoxanthine is then able to react with
oxygen to form xanthine which becomes uric acid with the
production of superoxide free radicals. The importance of this
reaction in man is uncertain as there is good evidence that the
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enzyme, xanthine dehydrogenase, is not present in human
myocytes (Eddy et at, 1987). However it is present in the
capillary endothelium so at least endothelial damage is possible
as a result of this reaction (Jarasch et al, 1986).
2) Activated neutrophils (Weiss, 1989)
The NADPH oxidase system is a membrane associated enzyme
complex that can generate oxygen centered free radicals when
the neutrophil becomes 'activated'. Electrons shuttle from the
cytosolic NADPH to oxygen molecules to produce superoxide
radicals. As a result of dismutation two superoxide radicals
form one molecule of hydrogen peroxide. At present it is
uncertain if the hydroxyl radical is produced by the activated
neutrophil generating hydrogen peroxide (Britigan et al, 1988).
It is perhaps unlikely that neutrophils contribute to the very
early (first 5 minutes) burst of free radical activity that may be
seen after reperfusion in a dog model of infarction (Bolli et al,
1988). Animal work indicates that neutrophil margination
within the reperfused vascular bed does not occur until at
least 20 minutes after the vessel has reopened (Sommers and
Jennings, 1964) and that neutrophil infiltration only follows a
coronary occlusion lasting more than 12 minutes (Go et al,
1988).
3) Mitochondrial electron transport
It has been proposed that ischaemia results in increased
leakage of electrons from the mitochondrial electron transport
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chain and these might generate free radicals (McCord, 1988).
Ischaemia could cause this by a decrease in the adenine
nucleotide pool and a loss of the myocardial defences against
oxidative damage (Ferrari et al, 1985).
4) Arachidonic acid metabolism
There is evidence that prostaglandin H synthetase and
lipoxygenase can generate superoxide radicals at least in vitro
(Rowe et al,1983; Kukreja et al, 1986).
5) Oxidation of catecholamines
It seems unlikely that 'autooxidation' of catecholamines is an
important source of free radicals as this process is very slow
at physiological pH (Jewett et al, 1989). However oxygen
centred free radicals may be produced as a result of catalysed
oxidations involving enzymatic systems and/or metal ions.
It is difficult to study free radicals in vivo because they are highly reactive
and are only present in very small concentrations at any given time. In
vitro techniques such as pulsed radiolysis are used to measure the
reaction constants for different chemical reactions involving free radicals
(Halliwell and Gutteridge, 1989). Briefly radicals are formed within a
reaction cell by a pulse of ionising radiation and the appearance and
disappearance of radical species can be detected by changes in the
absorbance characteristics over the following microsecond. By changing
the conditions and the chemicals within the chamber different radical
species can be studied.
Free radicals can be measured in biological systems using electron spin
resonance spectroscopy. The unpaired electron in a free radical behaves
as a very small magnet and will orient either with or against an applied
magnetic field. This results in the electron having one of two energy
states which can be detected by measuring the absorbance spectrum from
an external source of electromagnetic radiation. Electron spin resonance is
very sensitive but still requires the radical to remain long enough to be
measured. This problem can be circumvented by the use of a "spin trap",
a chemical which combines with highly reactive radicals and produces a
long lived more stable radical that can be more readily measured.
a-Phenyl-tert-butylnitrone (PBN) and 5,5-dimethylpyrroline-N-oxide (DMPO)
are examples of two such spin traps. These chemicals have been used to
detect free radical production in experimental animals but only in a limited
fashion in man (Coghlan et al, 1991). For example Bolli et al (1988) used
electron spin resonance spectroscopy with the spin trap, PBN, to detect
free radical species in their canine model of myocardial stunning.
An alternative approach that might be applicable to work in vivo is the
administration of an aromatic compound such as salicylic acid. The
hydroxyl radical reacts with salicylic acid to produce 2,3- and 2,5-
dihydroxybenzoates. The 2,3 isomer is not thought to be produced by
other enzymatic pathways and therefore the concentration should
represent hydroxyl radical formation (Grootveld and H a 11 iwe 11, 1986).
Other workers have suggested that the 2,5 isomer of dihydroxybenzoate
more closely reflects free radical activity (Udassin et al, 1991). Although
this method shows great promise it remains to be fully evaluated.
Free radical attack on lipids results in lipid peroxidation which can be
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quantified by a number of different methods, providing an indirect measure
of free radical activity. Diene conjugates (unsaturated fatty acids with two
double bonds only separated by one single bond) are formed early in the
process of peroxidation after the abstraction of a hydrogen atom from an
unsaturated fatty acid. This isomeric structure is favoured as it gives the
carbon centred radical more stablity. Conjugated dienes are detected by
measuring UV absorbance at 230-235 nm. Dormandy and his colleagues
have refined this method by including separation of biological material by
high performance liquid chromatography and also by the employment of
the ratio of native linoleic acid (18:2(9,12)) to its diene conjugate
(18:2(9,11)) (Iversen et al, 1985). This technique has been criticised by
Thompson and Smith (1985). They state that the diene conjugate of
linoleic acid is unlikely to be formed in vivo as the linoleic acid radical
would preferentially react with oxygen to produce a peroxy radical.
Instead these authors suggest that diene conjugates may arise from the
diet or the gut flora. However the oxygen tension in vivo is not always
high, for example in the myocardium of a patient after sudden coronary
occlusion. Conjugated diene levels are elevated in other disease states and
are thought to correlate with free radical activity e.g. alcoholic liver
disease (Hayes et al, 1989), preeclampsia (Erskine et al, 1985) and
rheumatoid arthritis (Lunec et al, 1981).
Lipid peroxidation can result in the formation of hydrocarbon gases and
these can be measured in exhaled air (Tappel and Dillard, 1981). This
process is favoured at low oxygen tensions but is complicated by liver
metabolism of the hydrocarbon gas and external pollution. For these
reasons the data from this technique is prone to error.
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One of the oldest and most frequently employed assays of lipid
peroxidation is the thiobarbituric acid test which involves heating
biological material with thiobarbituric acid under acid conditions and
detecting the formation of a pink colour by measuring absorbance at 532
nm. The basic reaction is between malondialdehyde, one of the many end
products of peroxidation, and thiobarbituric acid to produce a coloured
product. Unfortunately malondialdehyde is very reactive and the plasma
concentration is very low. Much of the measured malondialdehyde is
produced during heating from lipid peroxides present in the test tube. The
test has poor specificity as many other chemicals (various sugars,
biliverdin, sialic acid and haemolysed serum) react with thiobarbituric acid
to give a coloured product (Knight et al, 1988). Some workers have used
high performance liquid chromatography to separate the malondialdehyde-
thiobarbituric acid adduct and so increase specificity (Wong et al, 1987).
Unfortunately this still does not distinguish between malondialdehyde
produced by free radical lipid peroxidation and that from endoperoxides
produced by the prostaglandin synthesis pathway.
Rather than measuring free radicals or the products of free radical
reactions it is also possible to measure changes in biologically active
scavenging molecules (antioxidants). The main enzymatic antioxidants are
catalase, superoxide dismutase and glutathione peroxidase. ft-Carotene,
ascorbate, vitamin A, vitamin E and sulphydryl containing compounds are
the most important non-enzymatic scavengers of free radicals. McMurray
et al (1990) have measured the signal from reduced glutathione, an
intracellular free radical scavenger, in red cells by proton nuclear magnetic
resonance spectroscopy. Glutathione peroxidase, superoxidase and
vitamin E levels were assessed in a study by Beard et al (1992). These
indices are indirect and changes in their concentration/activity are not
necessarily related to free radical activity, but they are useful as
confirmatory tests.
Free radical involvement in reversible myocardial dysfunction after
ischaemia (myocardial stunning) has been well studied in animals. In a dog
model, reperfusion after 15 minutes of ischaemia resulted in free radical
production which was detected using a spin trap and electron
paramagnetic resonance spectroscopy (Bolli et al, 1988). In a different
animal model free radical activity associated with reperfusion increased in
parallel with the duration of the preceding ischaemia (up to 90 minutes)
(Arroyo et al, 1987). In other laboratory experiments dramatic reductions
in myocardial dysfunction after reperfusion were seen using a number of
agents that protect against free radical mediated damage (Myers et al,
1986; Bolli et al, 1987; Bolli et al, 1989). This effect was only seen when
these agents were administered prior to or at the time of reperfusion (Bolli
et al, 1989). A delay in treatment, by as little as one minute after the
restitution of flow, resulted in loss of effect.
A considerable number of laboratory studies have assessed the antioxidant
effect of superoxide dismutase on myocardial infarct size. Initial reports
indicated that superoxide dismutase therapy, started before reperfusion,
significantly decreased infarct size (Jolly et al, 1984; Werns et al, 1985;
Ambrosio et al, 1986). However more recently there have been many
other reports that failed to demonstrate any beneficial effect (Uraizee et
al, 1987; Richard et al, 1988; Nejima et al, 1989).
It has been suggested that the half life of superoxide dismutase in vivo is
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too short and that benefit would result from modification of the enzyme to
prolong its half life. Unfortunately the results of studies using modified
superoxide dismutase are still conflicting. Tamura et al (1988) and Chi et
al (1989) both found evidence of myocardial salvage whereas Ooiwa et al
(1989) and Tanaka et al (1989) did not find such activity.
The discrepancy between these results is now explicable since Przyklenk
and Kloner (1987a) demonstrated that superoxide dismutase only delays
myocyte necrosis when assessed by tetrazolium staining. If the
assessment of myocyte necrosis is histological and therefore by necessity
at least 24 hours after reperfusion then superoxide dismutase does not
reduce infarct size. This methodological artefact has been clarified by a
Japanese group who showed that 24 hours after reperfusion tetrazolium
staining indicated infarct size to be only 50% of the histological extent of
myocyte necrosis in animals treated with superoxide dismutase (Shirato et
al, 1989).
The lack of convincing benefit from treatment with superoxide dismutase
does not mean that free radicals are not important in causing myocyte
damage. It may be that a different scavenging agent is required. N-2-
mercaptoproprionyl glycine is an antioxidant which directly scavenges
hydroxyl radicals by virtue of its sulphydryl group and may reduce infarct
size. Mitsos et al (1986) studied this agent in a dog model of infarction
which included prior neutrophil depletion. Infarct size was decreased by
33% by reducing the number of circulating neutrophils and was
decreased further (by 63%) in those dogs that were treated by both
neutrophil depletion and N-2-mercaptoproprionyl glycine (MPG). Apart
from indicating a role for a free radical scavenger in reducing infarct size,
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this study suggests that free radical production during and after reperfusion
is not purely from activated neutrophils. The ability of MPG to cross cell
membranes may be important in permitting access to the site of radical
production and therefore explain why this agent is effective in
suppressing free radical damage (Lesnefsky, 1992).
There is evidence of free radical activity following myocardial infarction in
man, but its relationship to reperfusion is not clear. Clinical investigation
has demonstrated that conjugated diene levels are increased after
infarction. Bell et al (1990) found that neither the extent nor the timing of
this elevation was influenced by thrombolytic therapy. Grech et al (1992)
have also reported elevated levels of conjugated dienes in patients with
acute myocardial infarction but in their study this elevation occurred
within 10 minutes of successful primary angioplasty. The source of the
free radical marker appeared to be the myocardium as the blood samples
with the highest levels were drawn from a catheter in the coronary sinus.
Grech et al found that malondialdehyde levels were not increased either
before or in the 48 hours after angioplasty. A different group has reported
that free radical activity may be associated with successful thrombolysis
as they found an increase in malondialdehyde production 2 hours after
thrombolytic therapy in those with angiographic evidence of reperfusion
(Davies et al, 1990a). In contrast to the other reports conjugated diene
production was not increased in these patients. Using an alternative
marker of free radical activity Beard et al (1992) found that vitamin E
concentrations decreased over the first 48 hours after thrombolytic
therapy in patients with acute infarction. Workers from the USA have
shown that patients with myocardial infarction have significantly higher
breath pentane levels than patients admitted with chest pain without
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infarction (Weitz et al, 1 991). This study applied their measure of free
radical activity on admission prior to any attempt at therapeutic
reperfusion.
Further work is required to elucidate the relationship between free radicals
and reperfusion in man. The source of the free radical activity after
infarction remains unknown and it is still not clear if this activity is
clinically harmful by increasing the extent of myocyte necrosis in man.
Free radical scavenging agents that are beneficial in animal studies and are
non toxic will naturally require careful testing in man. The most promising
drugs are the membrane soluble sulphydryl containing compounds.
b) Calcium overload
One of the consequences of reperfusion observed in animal experiments is
a rapid and excessive influx of calcium ions into myocardial cells. This is
not seen in non reperfused myocardium and neither does it occur in
reversible ischaemic myocardial dysfunction following shorter periods of
coronary occlusion (Shen and Jennings, 1972a). Much of the calcium
appears as precipitates in mitochondria (Shen and Jennings, 1972b).
Greater calcium uptake is seen after longer periods of ischaemia and as
one would expect this correlates with a poorer recovery of myocardial
function (Bourdillon and Poole-Wilson, 1981). Calcium influx occurs at a
time when the cell membrane is not disrupted and the process can be
inhibited by nickel or cyanide ions (Poole-Wilson et al, 1984). However it
seems most likely that calcium influx occurs in myocytes that have




Reperfusion causes rapid and significant cellular oedema which is most
apparent in myocytes rather than the capillary endothelium (Kloner et al,
1974a). Within 2 minutes of reperfusion the myocardial water content
has risen by 20% (Whalen et al, 1974). This phenomenon is not seen in
non reperfused myocardium. By virtue of external capillary compression
the increase in intracellular water may be responsible for the observed
increase in coronary vascular resistance that follows reperfusion (Powers
et al, 1984), and may increase the ischaemic insult.
d) Intramvocardial haemorrhage
Permanent coronary artery occlusion results in an area of infarction that is
pale and not haemorrhagic. In animal studies between 44 and 100% of
infarcts are haemorrhagic following experimental mechanical reperfusion
(Bresnahan et al, 1974; Capone and Most, 1978; Roberts et al, 1983). In
the anaesthetised dog it is clear that haemorrhage only occurs in the
context of severe ischaemia in tissue that is already irreversibly injured
(Higginson et al, 1982). The extent of haemorrhage is greatest in the
endocardium and also in animals with the lowest collateral blood flow. In
addition in later experiments Higginson et al (1983) reported that the
extent of haemorrhage was greater when the duration of experimental
occlusion was longer. On histological examination haemorrhage is
confined to areas of necrosis (Higginson et al, 1982). Concern has been
raised that haemorrhage may increase infarct size as reported by
Bresnahan et al (1974). However this conclusion may be invalid as in this
animal study the extent of necrosis was only assessed by creatine kinase
curves and not by histology. It is reassuring that Roberts et al (1983)
reported haemorrhage to be associated with a lesser neutrophil infiltrate
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and no impairment of scar healing. Thus it seems likely that haemorrhage
is secondary to established necrosis and probably follows ischaemic injury
to the capillary endothelium. It is interesting that an animal study has
shown that streptokinase does not increase the extent of haemorrhage
beyond that seen after non thrombolytic reperfusion, despite the dramatic
effects that this drug has on the clotting cascade (Kloner and Alker,
1984).
In post mortem series the majority of patients who received streptokinase
had a grossly haemorrhagic infarct (Mathey et al, 1982; Waller et al,
1987). However, as these studies were limited to those who died after
thrombolysis, they may not be representative of the survivors who
received such therapy. In contrast to animal studies haemorrhage does not
appear to occur following mechanical reperfusion by primary coronary
angioplasty in man (Waller et al, 1987). There is continuing debate as to
the potential harm that might ensue from intramyocardial haemorrhage,
particularly after therapeutic thrombolysis. Delayed treatment with
thrombolytic agents may increase the incidence of cardiac rupture post
infarction (Mauri et al, 1987; Honan et al, 1991). Honan et al postulated
that dissection of blood between myocyte bundles might lead to tissue
disruption and cardiac rupture.
d) No reflow phenomenon
In 1966 Krug et al reported that temporary occlusion of a canine coronary
artery followed by reperfusion resulted in an area of absent perfusion in
the endocardium despite a widely patent epicardial vessel. The term 'no
reflow' phenomenon was applied several years later (Kloner et al, 1974b).
This latter group documented that this phenomenon was only apparent if
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the period of coronary artery occlusion lasted longer than 40 minutes.
They confirmed that it occurred predominantly in the endocardium and
they described the histological findings of extensive capillary damage and
myocardial cell swelling (contraction band necrosis). A later and more
detailed study of the time course of the ultrastructural changes following
ischaemia showed that microvascular damage lags behind myocyte
necrosis indicating that it is unlikely that the microvascular changes cause
myocyte injury (Kloner et al, 1980).
It has been suggested that 'no reflow' may be a result of myocardial or
endothelial cell swelling mechanically obstructing capillary flow.
Alternatively reperfusion studies indicate that microvascular plugging may
be caused by platelets (Feinberg et al, 1982) and neutrophils (Engler et al,
1983; Engler et al, 1986). Fibrin plugs per se are probably not responsible
for this lack of perfusion as it is still seen after streptokinase therapy
(Kloner and Alker, 1984).
It has become clear that the 'no reflow' phenomenon is more complex
than was initially thought. The extent of impairment of myocardial
perfusion gradually increases over the first few hours after reperfusion
(Ambrosio et al, 1989; Jeremy et al, 1990). The area of immediate no
reflow is characterised by severe coagulative necrosis on histological
examination and an absence of collateral flow during the ischaemic period
(Ambrosio et al, 1989). In contrast in areas of delayed impairment of flow,
histology reveals both contraction band necrosis, as has been described in
'reperfused' myocardium, and a significant intravascular accumulation of
neutrophils (Ambrosio et al, 1989).
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It is not surprising that neutrophil depletion in animal studies decreases
the impairment of perfusion which follows restoration of coronary flow
(Chatelain et al, 1987; Litt et al, 1989). In one report there was also a
decrease in infarct size in the neutrophil depleted group (Litt et al, 1989).
However persisting benefit from inhibition of neutrophil function was only
seen if this state was maintained for 48 hours after reperfusion, as
demonstrated in a study using a prostacyclin analogue infusion (Simpson
et al, 1988a). It is interesting that after reperfusion there is even
depressed blood flow in the reperfused epicardium that does not exhibit
necrosis. The importance of neutrophils in the 'no reflow' phenomenon
has not been confirmed in all studies. Neutrophil depletion failed to
prevent the impairment of perfusion that followed 2 hours of ischaemia in
the dog (Carlson et al, 1989).
If the 'no reflow' phenomenon exists and is harmful in man, then there
would be potential for therapeutic manipulation to improve myocardial
perfusion and perhaps salvage tissue. Evidence for this is still awaited but
the most likely target for such therapy is the acute inflammatory response.
f) Neutrophil activation
There is little doubt that neutrophils are involved in the process of
myocardial infarction. Early pathological studies demonstrated neutrophil
invasion within 24 hours of the onset of chest pain (Mallory et al, 1939;
Fishbein et al, 1978). Clinical studies have shown evidence of their
activation in the hours and days after infarction. Mehta et al (1989) drew
peripheral blood from patients within 1 hour of the onset of chest pain and
found altered neutrophil morphology and elevated levels of peptide B& (a
product of fibrin degradation by the neutrophil enzyme, elastase)
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confirming neutrophil activation. Similar activation was documented 3
days after infarction by Nash et al (1989) using morphological assessment
and measurement of white cell filterability. In our own laboratory, Bell et
al (1990) found increased plasma levels of neutrophil elastase which
persisted for up to 48 hours after infarction. Using nuclear imaging they
demonstrated myocardial uptake of autologous indium-1 11 labelled
neutrophils provided they were reinjected within 24 hours of the onset of
chest pain (Bell et al, 1987). Those patients who had received
thrombolysis had higher levels of plasma elastase early after infarction
although nuclear imaging revealed a relative decrease in myocardial
neutrophil uptake (Bell et al, 1990). In contradiction, Ranjadayalan et al
(1991a) found neutrophil elastase levels to be elevated 1 hour after
streptokinase infusion but to revert to normal within 6 hours. No attempt
was made to elucidate the time course of neutrophil activation over the
initial 2 hour period. In a more comprehensive report Ranjadayalan et al
(1991b) state that neutrophil activation was more marked in those with
reperfusion, but unfortunately this was only assessed 5 days later by
angiography. In addition they found a negative correlation between
elastase measurements and left ventricular ejection fraction. They
suggested that this was evidence of possible myocardial injury by
neutrophils. It is perhaps more likely that the neutrophil response is simply
dependent on the extent of infarction. Part of the discrepancy between
Ranjadayalan et al (1991a) and Bell et al (1991) may be accounted for by
the choice of different assays for elastase. The former used a commercial
kit that employed a double antibody sandwich enzyme linked
immunoadsorbent assay to elastase complexed to a 1 proteinase inhibitor
whereas the latter used a specific radioimmunoassay with rabbit
polyclonal antiserum to both free and complexed neutrophil elastase. In a
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more recent report Davies et al (1992) found increasing elastase
concentrations over the first 48 hours after the onset of pain and also a
significant correlation between the levels of elastase and thiobarbituric
acid reactive material, suggesting that neutrophils are a source of free
radicals later after myocardial infarction. Thus neutrophil activation occurs
after infarction, but the interaction between the human neutrophil and
thrombolysis mediated reperfusion remains to be fully elucidated.
Laboratory investigation suggests the activated neutrophil may be
involved in reperfusion injury which may result from other mechanisms
than simple mechanical capillary occlusion (discussed above). Activated
neutrophils produce oxidants that can mediate damage. The neutrophil
NADPH oxidase system produces superoxide radicals and hydrogen
peroxide. In addition neutrophil granules contain the enzyme
myeloperoxidase that is capable of catalysing the reaction of hydrogen
peroxide and chloride ions to produce the reactive oxidant, hypochlorous
acid (Harrison and Schultz, 1976). Activated neutrophils can generate
large quantities of this acid by this means (Weiss et al, 1982). Although
hypochlorous acid has little systemic toxicity when used to irrigate
surgical wounds, it is toxic when in direct contact with the delicate
vascular endothelium (Dakin, 1916; Johnson et al, 1987).
Another mechanism of neutrophil mediated injury involves the neutrophil
granule enzymes, of which the most important are the proteases: elastase,
collagenase and gelatinase (Weiss, 1989). Elastase has widespread
destructive properties, being able to degrade both extracellular matrix and
plasma proteins, and can even damage intact cells (Janoff, 1985). The
body defends itself against such proteinases by possessing powerful
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antiproteinases such as ayantiproteinase inhibitor, aymacroglobulin and
secretory leucoproteinase inhibitor (Janoff, 1985). In a fascinating
example of synergism the neutrophil uses its oxidant mechanisms to
facilitate damage caused by elastase and the other proteinases.
Neutrophil derived oxidants inactivate all three antiproteinases (Weiss et
al, 1984; Weiss et al, 1986; Kramps et al, 1987) and in addition they
activate the latent collagenase and gelatinase enzymes that are secreted
from neutrophil granules (Weiss et al, 1985; Peppin and Weiss, 1986).
Unfortunately the neutrophil's destructive powers are not selective once
stimulated and therefore this cell has the potential to damage viable cells
that lie adjacent to necrotic or injured cells. It is in this capacity that
neutrophils have been investigated as mediators of reperfusion injury.
Intervention experiments with animal models of coronary artery occlusion
and reperfusion have revealed promising results. Neutrophil depletion by
antibodies (Romson et al, 1983; Jolly et al, 1986) or leucocyte filters (Litt
et al, 1989) resulted in significant decreases in infarct size. Similar effects
have been obtained using antibody directed against leucocyte adhesion
molecules (anti-Mo1, anti-CD11b) (Simpson et al, 1988b; Simpson et al
1988c). Both prostacyclin (PGI2) and prostaglandin E1 (PGE.,) inhibit
neutrophil activation and have been shown to decrease infarct size in
animal models (Simpson et al, 1987a; Simpson et al, 1987b; Simpson et
al, 1988a; Simpson et al, 1988d).
The efficacy of these interventions depends on the duration of ischaemia
being relatively short (around 90 minutes). When coronary occlusion is
prolonged for 3 hours or longer no benefit is seen from reducing neutrophil
activity (Jolly et al, 1986; Chatelain et al, 1987). This may be because
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after this time the wave of coagulative necrosis has extended to include a
large part of the thickness of the myocardium and there is little possibility
of salvage of reversibly injured myocytes. Studies of neutrophil mediated
reperfusion injury have also shown a requirement for neutrophil function
to be suppressed for 48 hours after reperfusion if a long term beneficial
effect is to be seen (Simpson et al, 1988a).
g) Complement
The complement system in man comprises 20 proteins which have a key
role in orchestrating the acute inflammatory response (Muller-Eberhard,
1988). Activation normally occurs either through the classical pathway by
antigen antibody complexes or via the alternative pathway by a
heterogenous group of particles which include polysaccharides, fungi,
viruses, bacteria and some mammalian cells. Such complement activation
results in amplification of the acute inflammatory response (Goldstein,
1988).
Anaphylotoxins (C3a, C4a and C5a) are produced by the complement
pathway and cause increased capillary permeability, smooth muscle
contraction, histamine release and neutrophil activation (chemotaxis,
degranulation, increased oxidative metabolism, surface adherence and
expression of phagocytic (C3) receptors). Complement proteins are also
surface bound. In particular C3b and C3bi are potent opsonins that cause
phagocyte adherence and subsequent ingestion of coated particles or
ceils. In addition to amplifying the acute inflammatory response the
complement proteins are capable of inflicting direct damage to cells
through construction of the membrane attack complex (C5b-9). This
hydrophobic molecular complex inserts into cell membranes and forms a
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transmembrane channel that permits bidirectional ionic flow. If sufficient
numbers of these complexes are deposited on a cell membrane then cell
lysis results.
Animal studies confirm complement activation in relation to infarcted
tissue. In a baboon model of infarction without reperfusion there is
evidence of C3 deposition on myocardial cells within 4 hours of coronary
artery occlusion (Pinckard et al, 1980). After 24 hours there is extensive
C3 accumulation on necrotic or abnormal myocytes (Pinckard et al, 1980;
McManus et al, 1983; Crawford et al, 1988). In a rat experiment involving
coronary reperfusion after a period of ischaemia, investigators found
deposition of the membrane attack complex (C5b-9) along the capillary
endothelium as early as three hours after reperfusion (Weisman et al,
1990). This complement activity in association with the capillary
endothelium obviously has the potential to provoke a local intravascular
inflammatory response with capillary occlusion and augmented myocardial
damage. Electron microscopy on infarcted tissue from one of the animal
studies demonstrated complement protein associated with intracellular
structures: the contractile elements, nuclear membrane, mitochondrial
membranes and sarcoplasmic reticulum (Pinckard et al, 1980).
There is no doubt that the complement pathways are activated in acute
myocardial infarction in man. In peripheral blood samples complement
activation is evident within 16 hours of the onset of chest pain (Earis et
al, 1985; Langlois and Gawryl,1988; Yasuda et al, 1989; Yasuda et al,
1990). In a human autopsy study there were large quantities of the C5b-9
complexes in areas of infarction (Schafer et al, 1986). However, evidence
of complement activation was not found outside the infarcted zone and
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C4 deposition was not detected.
The mode of activation of the complement pathways by ischaemic or
necrotic tissue remains uncertain, but it is likely to occur by more than
one route. It is clear that the myocyte or endothelial cell must change in
response to ischaemia to enable complement activation to occur. Normal
human cells do not activate complement as they possess protective
inhibitory cell surface proteins (Muller-Eberhard, 1988; Goldstein, 1988).
It is not known if complement activation can be induced by a reversible
ischaemic insult, or whether a cell must suffer irreversible damage before
activation can occur.
Laboratory studies, both in vitro and in vivo, have shown that C1q is
capable of binding to proteins in mitochondrial membranes to cause
classical pathway activation (Pinckard et al, 1973; Pinckard et al, 1975;
Giclas et al, 1979; Rossen et al, 1988). There is also evidence that
mitochondrial membranes can activate the alternative pathway as C3
consumption continued even when the classical pathway was blocked
(Pinckard et al, 1975; Giclas et al, 1979). Similarly, Rubin et al (1990)
reported alternative pathway activation in a different experimental model.
Reperfusion of skeletal muscle after 5 hours of ischaemia was associated
with decreasing plasma levels of factor B.
Complement activation can proceed independent of the two recognised
pathways through direct action of proteases (eg trypsin or plasmin) on the
complement factors (Ratnoff and Naff, 1967; Taylor and Ward, 1967; Hill
and Ward, 1969). Within the area of an infarct proteases may be released
or generated locally and hence lead to the production of chemotactic
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fragments or full complement activation.
Depletion of complement activity has been reported to decrease infarct
size in animal studies and consequently the complement pathways have
been implicated as mediators of myocyte injury after ischaemia. Cobra
venom factor by binding to factor B to form a very powerful and stable C3
convertase can deplete all the components of the alternative pathway
including C3 and factors C5 to C9. Loss of these factors also paralyses
classical pathway activation. In non reperfused animal models of infarction
treatment with cobra venom factor reduces neutrophil infiltration and
ultimate infarct size (Maroko et al, 1978; Maclean et al, 1978; Pinckard et
al, 1980; Crawford et al, 1988). Other studies have emphasised the lack
of neutrophil infiltration after infarction in cobra venom treated animals
and in addition there is a lack of detectable chemotactic activity in either
the coronary sinus effluent or the myocardium of such animals (Hill and
Ward, 1975; Hartmann et al, 1977). There is no evidence that depleting
complement activity impairs infarct healing and scar formation (Maclean et
al, 1978).
Rather than depleting complement activity by activation an alternative
approach is to use a soluble inhibitory protein. Investigators have studied
the effects of soluble CR1 (sCR1) which binds C3b and C4 and also
promotes their inactivation by factor I. In the only study of complement
inhibition treatment with sCR1 reduced infarct size by 44% in a
reperfused rat model of myocardial ischaemic injury (Weisman et al,
1990). Complement inhibition, like depletion, did not impair infarct
healing.
Thus there is good reason to identify the complement pathway as a
mediator of reperfusion injury both in its own right and through its role in
the production of chemoattractants for neutrophils. Although complement
activation has been demonstrated in man following myocardial infarction,
it is not clear if this is initiated by reperfusion. Further thrombolytic agents
may interact directly with the complement pathway. Bennet et al (1987)
have already shown that recombinant tissue plasminogen activator
induces marked and immediate complement activation. This may be a
result of the direct action of plasmin on the complement proteins. The
effect of streptokinase has not been investigated in vivo but there is in
vitro evidence that it can cause complement activation (Ratnoff and Naff,
1967; Taylor and Ward, 1967).
FROM MYOCYTE NECROSIS TO SCAR FORMATION
If coronary occlusion prevents myocardial perfusion for longer than 20
minutes then necrosis will follow and the extent of necrosis increases
with the duration of preceding ischaemia (Reimer and Jennings, 1979).
The histological changes that follow myocyte necrosis have been reported
from autopsy studies (Mallory et al, 1939; Fishbein et al, 1978).
Neutrophil infiltration starts within 24 hours of coronary occlusion, but
does not reach its peak until 72 hours. Fibroblast proliferation, although
not evident until the fourth day after infarction, has become abundant by
the seventh day when there is also evidence of collagen deposition.
Concomitant with these processes macrophages remove the necrotic
myocytes by phagocytosis.
The progression from inflammation to healing and scar formation starts at
the periphery of the infarct and eventually reaches the centre (at least in
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patients not treated with thrombolytic agents). It may take as long as 5 to
6 weeks before all the necrotic tissue is removed. The fibrous scar
becomes increasingly dense over the next 2 to 3 weeks until it reaches a
maximum around 2 months after infarction. In vitro studies into the
physical properties of the scar tissue in left ventricular aneurysms confirm
that as the infarcted area heals to form a fibrous scar, it develops a
greater ability to resist stretch (Parmley et al, 1973).
During this healing process the heart is exposed to the haemodynamic
forces which tend to deform the ventricle. The net result is that a
proportion of patients undergo changes in ventricular size and shape
following infarction. This has been termed ventricular remodelling.
VENTRICULAR REMODELLING
Within a few minutes of coronary artery occlusion there is segmental
cessation of myocardial contraction and systolic bulging (Picard et al,
1991). These early changes are potentially fully reversible if flow is
restored prior to myocyte necrosis. Echocardiography shows that in man
ventricular dilatation may be evident within 24 hours of the onset of chest
pain following an acute myocardial infarct (Nieminen and Heikkila, 1976).
In a detailed study Eaton et al (1979) demonstrated that in a proportion of
patients (35%), there was progressive dilatation of the left ventricle over
the first 2 weeks. Longer term studies indicate that in some patients this
dilating process may continue for up to 6 months after infarction
(Erlebacher et al, 1982; Gadsboll et al, 1989; Jeremy et al, 1989).
The early phase (first 3 days) of ventricular dilatation is entirely due to
expansion of the infarcted segment (Erlebacher et al, 1984), whereas the
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later phase involves expansion of both the non infarcted and the infarcted
portions (Gadsboll et al, 1989). As the non infarcted segment expands it
may not undergo thinning. Instead the wall thickness may be maintained
in a similar fashion to volume overload hypertrophy (McKay et al, 1986).
However in larger infarcts there is thinning of the non infarcted segment in
addition to the infarcted segment as the ventricle is unable to compensate
(Olivetti et al, 1990).
Detailed histological analysis shows that in the infarcted zone dilatation
results from stretching of myocyte fibres, loss of intercellular space and
most importantly, side to side slippage of myocytes (Weisman et al,
1988). The increase in circumference of the non infarcted segment occurs
almost entirely from side to side slippage of myocyte bundles (Weisman et
al, 1988; Olivetti et al, 1990). These morphological changes do result in
haemodynamic improvement with lower filling pressures and a greater
cardiac output but at the expense of greater ventricular volumes (McKay
et al, 1986).
The mechanical forces that drive these changes in shape are the preload
(the diastolic distension of the ventricle) and the afterload (the resistance
against which the ventricle must contract in systole). The normal heart
can easily cope with the resulting wall stresses. In 1957 Burton wrote
emphasising that cardiac shape determines the level of wall stress in the
ventricle. After a myocardial infarct there is an increase in ventricular
cavity size and a decrease in wall thickness. As the law of Laplace would
predict these morphological changes increase wall stress. In a rat
experiment there was a greater than 7 fold increase in wall stress as a
result of a large infarct and this increase was evident in both the infarcted
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and the non infarcted zones (Olivetti et al, 1990).
The augmentation in wall stress is particularly marked in diastole and leads
to progressive ventricular dilatation as seen in ventricular hypertrophy
resulting from volume overload (Grossman et al, 1975). In this way an
enlarged ventricle is exposed to increased wall stresses and this in turn
provides the stimulus for further dilatation (Pfeffer and Pfeffer, 1987).
High wall stress also accounts for the propensity of apical infarcts to
dilate with aneurysm formation as the normal apex is the thinnest portion
of the ventricle and has the highest normal wall stress (Role et al, 1978).
Left ventricular remodelling does not always result in progressive
dilatation. Indeed there are observational studies documenting
improvements in ventricular size and function over the months and years
after myocardial infarction. Gaudron et al (1990) found that ventricular
volume decreased in small myocardial infarcts between 4 days and 4
weeks after infarction. A dramatic change was even recorded in a
selected group of patients with anterior myocardial infarction in whom the
mean ejection fraction increased from 26% to 41% over three years
(Silberberg et al, 1989). Although this measurement is only partly related
to ventricular volume, this result does imply a decrease in either end-
systolic or end-diastolic volume.
Ventricular dilatation is an adverse process following a myocardial infarct.
Human studies have shown that it is associated with a greater incidence
of cardiac failure (Erlebacher et al, 1982; Meizlish et al, 1984) and a
greater mortality (Eaton et al, 1979; Meizlish et al, 1984). The detrimental
effects of impaired ventricular function have been confirmed in a large
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prospective study of patients with coronary heart disease. The left
ventricular ejection fraction (i.e. stroke volume/end diastolic volume)
proved to be the most important predictor of survival, being more
important than the extent of coronary disease (Hammermeister et al,
1979). White et al (1987b) demonstrated the importance of ventricular
volumes, with end systolic volume being an even greater predictor than
ejection fraction for survival following acute myocardial infarction. Those
with an end systolic volume greater than 130 mis had a poor outcome
with only 52% surviving 5 years. The cause of death was 'sudden' in
70%, reflecting the increased incidence of malignant ventricular
arrhythmias in these patients. Only 8% died of cardiac failure. Patients
with ventricular remodelling and dilatation are also at risk of mural
thrombus formation with a proportion being complicated by systemic
embolism (Asinger et al, 1981; Keren et al, 1990). It has been suggested
that if the dilating process is rapid in the days after infarction, then
cardiac rupture either of the free wall or of the interventricular septum can
result (Schuster and Bulkley, 1979).
Ventricular dilatation following myocardial infarction is not uncommon but
the reported incidence varies widely depending on the selection of the
study population. In autopsy series the incidence of dilatation post
infarction lies between 45% and 60% (Hutchins and Bulkley, 1978; Pirolo
et al, 1986). Observational clinical studies in unselected patients with
acute myocardial infarction indicate a lower incidence of 40% (Jeremy et
al, 1987; Jeremy et al, 1989). Two groups, restricting patient selection to
those with transmural infarction, report widely differing incidences of
28% (Eaton et al, 1979) and 55% (Warren et al, 1988). If assessment is
limited to cases of anterior transmural infarction, the incidence is higher at
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57% (Erlebacher et al, 1984). However frank aneurysm formation, an
extreme form of remodelling, was only documented in 35% of cases of
transmural anterior infarcts (Meizlish et al, 1984). Animal models of acute
infarction involving coronary ligation report similar figures to the human
study of transmural anterior infarcts with greater than 60% of animals
exhibiting ventricular dilatation (Hochman and Bulkley, 1982; Weisman et
al, 1985).
REMODELLING: RISK FACTORS AND POSSIBLE MODIFICATION
1) Site and size of infarction
Autopsy studies confirm the importance of large and transmural infarcts in
the pathogenesis of left ventricular dilatation (Hutchins and Bulkley, 1978;
Pirolo et al, 1986). However the relationship between ventricular
enlargement and infarct size has not been borne out in all studies. Eaton
et al (1979) found no significant difference in infarct size as assessed by
peak creatine kinase between those patients who did and did not exhibit
ventricular expansion. The site of infarction is also important as dilatation
is more common after necrosis in the left anterior descending coronary
artery territory (Warren et al, 1988).
Animal models of infarction indicate that there is a threshold for infarct
size below which dilatation is not seen. In the dog above this threshold,
ventricular dilatation does occur but the extent of enlargement does not
correlate with infarct size (Eaton and Bulkley, 1981; Weisman et al,
1985). In contrast investigation using the rat model has demonstrated a
correlation between cardiac dilatation and infarct size which may be a
consequence of the relatively poor collateral circulation in this species
(Hochman and Bulkley, 1982). Animal studies confirm that remodelling is
not seen in nontransmural infarcts (Eaton and Bulkley, 1981).
2) Patency of the infarct related artery
There is evidence from animal studies to indicate the importance of
coronary artery patency. Hochman and Choo (1987) demonstrated that
reperfusion after 30 minutes in a rat model of infarction results in a
reduction in infarct size, in the transmural extent of the infarct and in
infarct expansion over the subsequent 2 weeks. If reperfusion is delayed
until 2 hours after occlusion then infarct size and the transmural extent of
the infarct are not reduced. However late reperfusion does reduce infarct
expansion. In a similar study Hale and Kloner (1988) examined the effects
of reperfusion after 30 and 90 minutes in a rat model of infarction. Early
reperfusion completely inhibits ventricular dilatation and scar thinning.
Later reperfusion is followed by some ventricular dilatation but does
prevent gross expansion and scar thinning.
In man persisting occlusion of a coronary artery following acute
myocardial infarction has proven to be one of the most important risk
factors for ventricular dilatation. In an observational study the degree of
perfusion of the infarct related artery was the most important predictor of
volume change following infarction as assessed by multiple linear
regression analysis (Jeremy et al, 1987). Likewise, in a different study,
left ventricular function improved over the first two weeks after infarction
in patients with spontaneous reperfusion, whereas those patients with
persisting occlusion suffered a decline in ejection fraction (Verheugt et al,
1986). The benefit of spontaneous reperfusion was confirmed in another
study which in addition found that streptokinase induced reperfusion
(within 3 hours of the onset of chest pain) resulted in even better
preservation of ventricular function (De Feyter et al, 1983).
Over the last 10 years there have been a large number of placebo
controlled studies of thrombolytic agents. The more detailed have included
coronary angiography and as a result patency of the infarct related artery
has been identified to be associated with both improved preservation of
ventricular function and prevention of ventricular dilatation (Touchstone et
al, 1989; Lavie et al, 1990). In addition some studies were able to
demonstrate a lower mortality in those with successful reperfusion
(Kennedy et al, 1985; Dalen et al, 1988). Despite all this evidence
supporting the importance of a coronary artery patency, there is one study
which failed to show prevention of ventricular dilatation following
successful thrombolysis (Warren et al, 1988). This was a small study in
which thrombolysis was administered relatively late after the onset of pain
and on its own does not nullify the evidence that reperfusion is valuable.
The larger placebo controlled trials of thrombolytic therapy clearly
demonstrate a lower mortality in the groups receiving active treatment
(GISSI, 1986; Kennedy et al, 1988; Meinertz et al, 1988; AIMS trial study
group, 1988; Wilcox et al, 1988). Although some of this effect may be a
result of reduction in infarct size, at least part of the benefit appears to be
mediated by the ability of a patent artery to prevent ventricular dilatation.
In particular in the ISIS-2 study there was a significant reduction in
mortality in the group treated with both streptokinase and aspirin even
when treatment was initiated late, between 12 and 24 hours after the
onset of pain (ISIS-2, 1988). It is very unlikely that myocardial salvage
with a reduction in infarct size would have been achieved by thrombolysis
so late in the evolution of an infarct. The most likely explanation is that
aspirin and thrombolytic therapy result in a patent coronary artery that
reduces the tendency to ventricular dilatation.
Percutaneous transluminal coronary angioplasty is an alternative method
that may be used to remove an occlusive coronary thrombus. However
the role of angioplasty in infarction is still under debate. It is clear that
there is no place for early angioplasty after thrombolysis if it is only to
remove a residual stenosis in a patient without recurring chest pain (Topol
et al, 1987; Simoons et al, 1988; TIMI Study group, 1989). Such
treatment is associated with an increased incidence of complications and
mortality.
Angioplasty for patients where thrombolysis has failed to reopen the
occluded artery may be advantageous and may result in an improvement
in left ventricular function as demonstrated in a non randomised series by
Fung et al (1986). Guerci et al (1987) assessed the impact of angioplasty
3 days after thrombolysis in a randomised study. Unfortunately the study
population was heterogenous as patients were eligible for randomisation if
there was a suitable stenosis of greater than 70 % or if the infarct related
artery was occluded. Although there was no difference in ultimate resting
ejection fraction, the patients undergoing early angioplasty had a
significantly greater increase in ejection fraction with exercise. These
results are encouraging but the problem remains to be tested in a formal
study where patients with myocardial infarction who have persisting
occlusion of a coronary artery despite thrombolytic therapy are
randomised to either angioplasty or conservative therapy.
Why should a patent coronary artery decrease ventricular dilatation? The
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answer to this question has not been resolved, but there are several
different theories to consider. Firstly, reperfusion may make the infarcted
zone stiffer and more resistant to dilatation as reopening the artery results
in intramyocardial haemorrhage, oedema and contraction band necrosis
(Althaus et al, 1976; Roberts et al, 1983). In keeping with this theory
Force et al (1988) have confirmed that there is an acute reduction in the
expansion of an infarct zone in a dog model within 3 hours of delayed
reperfusion. Secondly, it has been postulated that the quality of scar
tissue is better when preceded by reperfusion. However this was not
borne out in a study of rabbit myocardial scar tissue which found no
difference in the tensile strength of the scar between infarcts that had and
had not undergone reperfusion (Connelly et al, 1985). A third theory
suggests that reperfusion is advantageous as it accelerates healing and
removal of necrotic tissue. This is supported by evidence from
experimental infarction in pigs where reperfusion resulted in more rapid
removal of necrotic tissue and more rapid appearance of granulation tissue
(Althaus et al, 1977). Braunwald (1989) has suggested that an open
artery may provide a viable vascular scaffolding that might limit
expansion. Lastly, reperfusion may exert its effect by improving viability
and function of the remaining epicardial rim of myocytes (Pfeffer and
Braunwald, 1990). These myocytes might then be able to oppose
dilatation in a similar way to recovery of hibernating myocardium after
revascularisation.
3) Drugs that influence infarct healing
The greatest change in ventricular volume occurs in the early days and
weeks following myocardial infarction while the infarct is healing. It is not
surprising that drug therapy that delays or inhibits this process can have
deleterious effects. A case report and a clinical study suggest that
corticosteroids are harmful after infarction predisposing to aneurysm
formation, increasing infarct size and increasing the incidence of
ventricular dysrhythmias (Bulkley and Roberts, 1974; Roberts et al, 1976).
In a similar way Boden and Sadaniatz (1985) report a possible relationship
between ibuprofen therapy (a non steroidal anti inflammatory agent) and
the incidence of ventricular septal defect complicating myocardial
infarction.
Animal studies confirm that both corticosteroids and non steroidal anti
inflammatory agents increase the tendency to ventricular dilatation with
extensive thinning of the infarct segment. Both Maclean et al (1978) and
Hammerman et al (1983a) demonstrated that high dose and prolonged
methylprednisolone therapy resulted in these adverse morphological
changes. These effects were not seen following a single lower dose
injection at the time of coronary artery occlusion. However the collagen
content of the scar did not change even after high dose steroid therapy
(Hammerman et al, 1983a). Studies of experimental infarction in dogs
report that indomethacin given early after coronary occlusion results in
marked scar thinning when assessed after either 1 or 6 weeks
(Hammerman et al, 1983b; Hammerman et al, 1984). Although there is
some evidence that ibuprofen can reduce infarct size (Jugdutt et al, 1980;
Romson et al, 1982), it has also been reported to cause scar thinning and
dilatation (Brown et al, 1983; Jugdutt, 1985). The evidence concerning
ibuprofen is conflicting as Cannon et al (1985) found that ibuprofen did
not cause excessive scar thinning even when given to rats for 6 days
following experimental coronary artery ligation.
The mechanism of corticosteroid action has been investigated in a rat
model of infarction. The detrimental effect is seen early as the excessive
infarct thinning does not increase after the third day post coronary
occlusion (Mannisi et al, 1987). At the cellular level the infarct zone is
seen to thin as a result of excessive slippage of necrotic myocytes.
Steroid therapy reduces the influx of phagocytes into the necrotic
myocardium and results in a significant delay in the removal of the
necrotic myocytes which Kloner et al (1978) term 'mummification'.
4) Ventricular loading conditions
Infarct thinning and ventricular dilatation can be aggravated by increasing
the afterload. In an isolated heart acute diastolic expansion during
ischaemia is more marked in association with a high afterload and is
reversed by reducing the afterload (Nicklas et al, 1983) . Aortic banding to
increase intraventricular pressure and induce hypertrophy is associated
with increased infarct expansion following coronary occlusion in rats
(Nolan et al, 1988). However the same research group has previously
reported conflicting results showing that aortic banding reduces
expansion after infarction (Weismann et al, 1984). In dogs
pharmacological intervention with methoxamine, an alpha adrenergic
agonist, increases the afterload and results in greater expansion and
thinning of the infarct zone (Hammerman et al, 1985). Similarly, clinical
investigation confirms that increased arterial pressure and increased
systemic vascular resistance are risk factors for ventricular dilatation after
infarction (Pierard et al, 1987).
Physical exercise is an alternative and physiological method of increasing
cardiac work. Cardiac output and systolic blood pressure increase during
exertion. Regular exercise produces left ventricular hypertrophy with an
increase in muscle mass (Pfeffer et al, 1978). There are conflicting reports
concerning the effects of exercise on the myocardium during the healing
phase after myocardial infarction. Some animal studies show evidence of
thinning and infarct expansion following regular exercise (Sutton and
Davies, 1931; Hammerman et al, 1983c; Kloner and Kloner, 1983), while
other studies fail to show any detrimental effects (Thompson et al, 1973;
Hochman and Healy, 1986). It is relevant that in a clinical study a low
level exercise training programme produced detrimental dilatation
following transmural anterior infarction if the left ventricle had significantly
impaired function (defined in this study as asynergy greater than or equal
to 18%) (Jugdutt et al, 1988a). Thus there is reason to suspect that in
some patients the additional stress of an exercise programme may be
harmful during the healing phase.
VASODILATOR THERAPY
Vasodilator drugs have been used to reduce the forces that drive
ventricular dilatation either by decreasing preload, afterload or both. Most
studies have employed the nitrate vasodilators or angiotensin converting
enzyme inhibitors.
a) Nitrate vasodilators
There is compelling evidence that intravenous nitroglycerin therapy in the
early hours following acute myocardial infarction reduces the tendency to
infarct thinning and dilatation (Jugdutt and Warnica, 1988b). The benefit
in this study was seen despite the mean duration of treatment being only
39 hours. A more recent clinical study confirmed the advantageous effect
of nitroglycerin therapy after myocardial infarction on ventricular volumes
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both at rest and during exercise (Humen et al, 1989). Randomised
mortality studies of intravenous nitroglycerin after myocardial infarction
have been performed and the individual results are inconclusive (Flaherty
et al, 1983; Jaffe et al, 1983; Jugdutt and Warnica, 1988b). However a
statistical overview of all randomised clinical studies found a clear
reduction in mortality after intravenous nitroglycerin therapy initiated early
after myocardial infarction (Yusuf et al, 1988).
The beneficial results of nitroglycerin therapy may not only result from its
haemodynamic effects reducing preload and afterload. Part of its action
may be to decrease infarct size and to increase collateral coronary blood
flow - both of these being established risk factors for ventricular
remodelling. In dog studies intravenous nitroglycerin increases collateral
flow after coronary artery occlusion (Capurro et al, 1977) and results in a
smaller area of ischaemic injury (Chiariello et al, 1976). The effect of
nitroglycerin on infarct size is not dependent on a fall in blood pressure
and it is therefore probably related to the increase in oxygen supply from
collateral blood flow rather than a decrease in oxygen demand (Jugdutt et
al, 1981). Moreover nitroglycerin therapy ceases to be beneficial and may
be detrimental if there is excessive hypotension as has been demonstrated
in both animal and clinical studies (Jugdutt, 1983; Jugdutt and Warnica,
1988b).
Intravenous nitrates are also able to influence platelet function by
inhibiting platelet aggregation. This was demonstrated in 11 patients with
angina receiving an infusion of isosorbide dinitrate (De Caterina et al,
1984). More recently Diodati et al (1990) reported that intravenous
nitroglycerin significantly inhibited platelet aggregation in 10 patients with
acute coronary syndromes. It seems likely that this effect on platelet
function would benefit patients with infarction in a similar way to aspirin.
b) Angiotensin converting enzyme inhibitors
The angiotensin converting enzyme inhibitors are another group of
vasodilators that might be beneficial in preventing ventricular remodelling
following myocardial infarction. These drugs cause dilatation of the
venous and arterial vascular beds and so reduce preload and afterload.
The rationale for their use in myocardial infarction is underlined by studies
of the response of the renin angiotensin system to this condition.
Angiotensin II levels rise following myocardial infarction and reach a peak
on the third day (McAlpine et al, 1988). If a patient has heart failure
following infarction then the levels are greatly increased (Michorowski and
Ceremuzynski, 1983; McAlpine et al, 1988). Elevated levels are even
found in patients with asymptomatic left ventricular dysfunction who are
not on diuretic therapy (Vaughan et al, 1990).
As a consequence of this increased renin - angiotensin activation both the
peripheral vascular resistance and the cardiac work load are increased at a
time when the heart is least able to cope with it. As well as increasing the
peripheral vascular resistance, angiotensin II is a powerful coronary artery
vasoconstrictor (Drimal, 1968) and a positive inotrope (Koch-Wesser,
1965). By increasing the haemodynamic forces and decreasing coronary
blood flow increased angiotensin II levels potentiate the tendency to
ventricular dilatation.
Animal studies have shown that the angiotensin converting enzyme
inhibitor, captopril, is beneficial following myocardial infarction. In a rat
model of infarction involving permanent ligation of the anterior descending
coronary artery Pfeffer et al showed that captopril treatment would
decrease ventricular dilatation (1985a) and improve survival (1985b). In
both these studies the greatest effect was seen in those animals with
moderate sized as opposed to large or small infarcts. In animal
experiments there was no additional benefit from starting treatment
within the first two days of infarction as opposed to delaying the
introduction of captopril until 3 weeks after infarction (Pfeffer et al,
1985a; Gay, 1990). However it has been suggested that early captopril
therapy following a myocardial infarct might have several advantageous
consequences in man. The evidence is reviewed below.
i) Infarct size reduction
Captopril therapy reduces infarct size in some animal models of infarction.
Ertl et al (1982) demonstrated a significant reduction in infarct size in
captopril treated dogs that had undergone surgical occlusion of a coronary
artery. This effect was associated with an increase in collateral blood flow
into the ischaemic zone in the treated animals. Infarct size was also
decreased by captopril therapy in a pig model of infarction which included
a period of reperfusion after 1 hour of ischaemia (De Graeff et al, 1987).
The effect was greater following a larger dose of captopril (up to 6
mg/kg/10 min). Other angiotensin converting enzyme inhibitors are
capable of infarct size reduction as was seen in a study by Hock et al
(1985) using enalaprilic acid. However a beneficial effect on infarct size
has not been reported by all investigators. Both Daniell et al (1984) and
Liang et al (1982) failed to demonstrate any modification in infarct size as
a result of captopril therapy in dogs after permanent occlusion of the left
anterior descending coronary artery.
ii) Free radical scavenger
Captopril is a free radical scavenger in vitro (Bagchi et al, 1989a; Chopra
et al, 1989; Mak et al, 1990). This property is thought to be related to the
presence of a sulphydryl group in its chemical structure as the other non
sulphydryl containing angiotensin converting enzyme inhibitors do not
have the same activity (Westlin and Mullane, 1988; Mak et al, 1990).
Although there is work showing that captopril does not scavenge the
superoxide radical (Kukreja et al, 1990), there is general agreement that it
is active against the hydroxyl radical (Bagchi et al, 1989a; Mak et al,
1990). Indeed captopril inhibits malondialdehyde formation, a product of
free radical activity, in an ischaemic isolated rat heart preparation (Bagchi
et al, 1989b).
iii) Limitation of post ischaemic dysfunction (stunning)
There is evidence that captopril limits reversible myocardial dysfunction
after a short period of ischaemia, also known as myocardial stunning
(Patel et al, 1988). This is of relevance in acute myocardial infarction as
there is not a sharp boundary between normal and abnormal myocardium.
There is a zone around the infarct that is ischaemic but not necrotic and
hence will experience myocardial stunning which may take several days to
return to normal function. In 1988 Westlin and Mullane reported that both
captopril and a stereoisomer without angiotensin converting enzyme
inhibitor activity reduced post ischaemic contractile dysfunction. In
addition both agents reduce the incidence of ventricular tachyarrhythmias
occurring after reperfusion. These effects were attributed to the
sulphydryl group and its proposed free radical scavenging ability. However
other vasodilators, enalapril and hydralazine, also improve post ischaemic
contractile dysfunction although neither possesses a sulphydryl group
(Przyklenk and Kloner, 1987b). A recent report by Przyklenk and Kloner
(1990) indicates that sulphydryl containing and non sulphydryl containing
angiotensin converting enzyme inhibitors both reduce myocardial stunning
after ischaemia but probably by different mechanisms. The beneficial
effect of enalaprilat is blocked by the administration of indomethacin
demonstrating that this drug's action is mediated by prostaglandin
synthesis (probably PGE1 and PGI2). However zofenopril, a sulphyhryl
containing angiotensin converting enzyme inhibitor, also reduces
myocardial stunning but this effect is not inhibited in this way and the
authors suggest that free radical scavenging may account for its action.
iv) Modulation of the inflammatory response
There is increasing evidence that angiotensin II is an inflammatory
mediator and that inhibition of its production by angiotensin converting
enzyme inhibitors has anti inflammatory effects. There are receptors for
angiotensin II on human mononuclear leucocytes and tissue macrophages
(Shimada and Yazaki, 1978; and Weinstock and Kassab, 1984).
Angiotensin II, at least in vitro, increases macrophage binding and
phagocytosis of particles via Fc and C3b receptors (Foris et al, 1983). A
more recent study has revealed that angiotensin II augments free radical
generation in normal human neutrophils (Prabha et al, 1990). Angiotensin
II also has an indirect effect on neutrophil function as it causes the release
of a chemoattractant from endothelial cells (Farber et al, 1990). Moreover
tetrapeptide fragments of angiotensin II have direct chemotactic activity
on monocytes (Goetzl et al, 1980).
In light of these actions of angiotensin II, it is not surprising that captopril
has anti inflammatory effects in a variety of situations. It inhibits vascular
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permeability changes caused by a number of different acute inflammatory
mediators (Fantone et al, 1982). In a mouse model of schistosomiasis
angiotensin converting enzyme inhibitors decreases granuloma formation
(Weinstock et al, 1981; Weinstock and Blum, 1983). Lastly, captopril has
been used successfully as an anti inflammatory agent in rheumatoid
arthritis (Martin et al, 1984). It is interesting that the molecular structure
of captopril is not dissimilar to that of penicillamine which is accepted as
an effective drug in the treatment of rheumatoid arthritis.
CLINICAL STUDIES WITH CAPTOPRIL
Captopril therapy following myocardial infarction has been studied in
clinical trials, and results show a significant benefit from drug therapy.
However the details of the therapeutic protocol and patient selection have
varied in these studies with the result that general application of this
therapy to all patients with acute myocardial infarction has not been
tested.
In 1988, Sharpe et al published the first report that captopril therapy
prevents ventricular dilatation in patients with symptomless left ventricular
dysfunction. This group selected 60 patients with Q wave infarction that
had an echocardiographic ejection fraction of less than 45% but no clinical
evidence of heart failure. Trial therapy with captopril 25 mg three times
daily, frusemide 40 mg daily or placebo was started 1 week after acute
myocardial infarction. No patient in this study received thrombolysis and
the percentage of patients treated with aspirin was not recorded in this
paper. The captopril treated group showed a decrease in ventricular
volumes and an increase in ejection fraction whereas both the placebo and
frusemide treated groups suffered ventricular dilatation and a fall in
ejection fraction. These changes were evident at the first assessment
(after 1 month). After 3 months the differences were established and they
were maintained for the 12 month follow up period. The same group
reported similar findings in a second report after the study population had
risen to 90 patients (Sharpe et al, 1990).
Pfeffer et al also reported the results of a clinical study in 1988 which
examined 59 patients who had been admitted to hospital with their first
anterior Q wave infarct and had a radionuclide ejection fraction less than
45% without evidence of overt heart failure. Trial therapy consisted of
either captopril (up to 50 mg three times daily) or placebo and this was
initiated a mean of 20 days after the acute myocardial infarct. As in the
study of Sharpe et al (1988), patients treated with thrombolytic agents
were not included. In this study captopril was only of benefit in patients
who were at high risk of ventricular remodelling because of persisting
occlusion of the left anterior descending coronary artery.
In 1991, Sharpe et al reported a further study which now included
patients treated with thrombolytic agents but still restricted eligibility to
those with Q wave infarction. One hundred patients were randomised to 3
months treatment with either captopril 50 mg twice daily or placebo.
Treatment was started much earlier in this study, between 24 and 48
hours after the onset of ischaemic chest pain. Once more captopril
therapy prevented ventricular dilatation in this high risk group. In this trial
additional assessment of left ventricular function was made 48 hours after
withdrawal of drug therapy to counter the criticism that the previously
observed effect was simply due to the acute pharmacological effects of
captopril reducing the afterload and preload. It could be argued that 48
n
hours is still too short a time for all captopril's actions, particularly as an
inhibitor of tissue angiotensin converting enzyme, to have vanished
(Cohen and Kurtz, 1982). Accepting this limitation, the observed benefit
remained after withdrawal of the trial therapy.
A group in Glasgow have published their findings in a two-centre study of
99 patients with acute myocardial infarction (Oldroyd et al, 1991).
Patients with acute myocardial infarction were randomised to either
captopril 25 mg three times daily or placebo within 48 hours of the onset
of chest pain. They were required to have significant ST segment
elevation and a Norris score of greater than 3.5. This study also excluded
patients receiving thrombolysis. Infarct segment expansion as measured
by echocardiographic endocardial segment lengths was less in those
treated with captopril. As predicted the effect was most pronounced in
patients with anterior infarction.
These studies clearly show that captopril is of benefit in selected patients
that are at high risk of ventricular remodelling. In view of the importance
of permanent coronary artery occlusion in this process it seems likely that
therapy with either thrombolytic agents or aspirin would modify the role of
angiotensin converting enzyme inhibitors after infarction. In addition it is
not clear if there is any additional benefit or detriment from very early
treatment with such an agent.
The general administration of angiotensin converting enzyme inhibitors to
all patients following infarction is being assessed in a number of
multicentre trials with mortality as the main endpoint (eg ISIS 4, GISSI 3,
SMILE, TRACE, AIRE and the Chinese captopril study). Two large
multicentre studies have very recently published their results. Swedberg et
al (1992) found that early enalapril therapy did not reduce 180 day
mortality in the CONSENSUS II (Cooperative New Scandinavian Enalapril
Survival Study) study. Their protocol included all patients with infarction
without hypotension. In contrast the SAVE (Survival and Ventricular
Enlargement) study found a reduction in mortality in patients treated with
captopril therapy after infarction (Pfeffer et al, 1992). The SAVE protocol
delayed randomisation to later than 3 days after infarction and carefully
selected patients with an ejection fraction less than 40% who did not
have evidence of ischaemia. It is evident that further information is
required before the role of vasodilators after infarction can be decided.
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UNRESOLVED ISSUES
Understanding of the pathophysiology of acute myocardial infarction has
grown over the last 15 years and, following large multicentre trials, has
led to dramatic changes in the management of this condition.
Thrombolytic agents are now widely used in acute myocardial infarction
to lyse occluding intracoronary thrombus. Aspirin has become routine
therapy both acutely and long term after infarction, at least in part to
reduce the rate of coronary reocclusion (ISIS-2, 1988).
The role of angioplasty in infarction is still under debate. There is no doubt
that this technique is capable of reducing coronary artery stenoses and
recanalising occluded vessels. It is possible that angioplasty may benefit
patients who have persisting coronary artery occlusion despite
thrombolytic therapy, but this remains to be tested scientifically. In
addition the timing of such intervention may be important and requires
investigation.
The mechanism by which coronary reperfusion confers benefit is not
entirely clear. If the artery is reopened early (<3 hours) then there is
considerable evidence that myocardium can be salvaged, but it seems
unlikely that this is true for later reperfusion. Ultimate patency of a
coronary artery or at least perfusion of a coronary bed appears to be
important in preventing progressive ventricular dilatation and the related
detrimental consequences.
Reperfusion therapy initially caused great fears of myocyte injury resulting
from oxygenated blood entering an ischaemic myocardial bed.
Nevertheless there seems little doubt that if reperfusion injury exists, it
causes less damage than would have occurred if the artery had remained
closed. It is still not clear if adjuvant therapy might improve myocardial
salvage after reperfusion. Animal models employing the free radical
scavenger, superoxide dismutase, have been disappointing. Modulation of
complement or neutrophil function appears more hopeful as a method of
decreasing infarct size. Caution should be emphasised when attempting to
reduce the inflammatory response as detrimental scar thinning and
expansion may result as has been reported with steroids and non steroidal
anti inflammatory agents in experimental infarction.
Ventricular dilatation is a consequence of myocardial infarction which may
be amenable to modulation by vasodilator therapy. Certainly there is
evidence that selected high risk patients benefit from this type of
intervention. The exact role of vasodilators when administered in
conjunction with the established therapies for acute infarction remains to
be elucidated. In addition vasodilator therapy may have beneficial effects
separate from the physical effects of the haemodynamic changes on the
process of ventricular dilatation, particularly if it is administered early after
infarction. Experimental studies suggest that some vasodilators may
reduce infarct size and modulate the acute inflammatory response.
Ventricular rupture is a complication of acute myocardial infarction that
may be a consequence of infarct expansion or possibly intramyocardial
haemorrhage. There has been debate recently concerning the impact of
thrombolysis on this complication. There is evidence to suggest that
thrombolysis may reduce the incidence if administered early after coronary
occlusion. It is not certain if this therapy might predispose to cardiac
rupture by intramyocardial haemorrhage if treatment is delayed.
Clearly there are a great number of unresolved issues which will require
further investigation. In addressing the question of how best to limit left
ventricular dysfunction after acute myocardial infarction I have examined
the following aspects:
1) What is the role of early oral vasodilator therapy in acute myocardial
infarction in an average patient presenting with chest pain and ST
elevation, who is likely to receive thrombolytic therapy?
2) Is there evidence that early oral vasodilator therapy as used in 1) can
modulate either infarct size or the acute inflammatory response?
3) Considering the importance of thrombolytic reperfusion and the acute
inflammatory response in dictating infarct size and the propensity to
ventricular dilatation, is there evidence of interactions either beneficial or
detrimental between streptokinase, reperfusion and the acute
inflammatory response?
4) Infarct expansion and/or intramyocardial haemorrhage may be involved
in the pathogenesis of cardiac rupture post infarction (including rupture of
the interventricular septum). What impact has the advent of thrombolytic
therapy had on the presentation of ventricular septal rupture as seen in
the Royal Infirmary of Edinburgh over the last 7 years?
Each section is presented with a brief introduction, an outline of the
methodology used, the results and subsequent discussion of these results.
The final section attempts an overview of these issues and suggests
appropriate changes in therapy that might limit myocardial dysfunction
after acute myocardial infarction.
CHAPTER 2
THE ROLE OF VASODILATOR THERAPY IN THE
MANAGEMENT OF ACUTE MYOCARDIAL
INFARCTION
INTRODUCTION
In selected patients vasodilator therapy has been shown to prevent post
infarction ventricular dilatation (Sharpe et al, 1988, Pfeffer et al, 1988,
Sharpe et al, 1991). It is not known if this is true for all patients,
particularly those treated by thrombolysis.
The aim of this study was to evaluate early oral vasodilator therapy with
either captopril or isosorbide mononitrate in an unselected group of
patients with acute myocardial infarction and therefore assess their role
in the typical infarct patient. Left ventricular size and function were the
main endpoints with the clinical outcome being a secondary endpoint.
METHODS
Study Protocol
Patients admitted to the coronary care unit with suspected acute
myocardial infarction were eligible for study, if they presented within 24
hours of the onset of typical chest pain, with ST elevation and systolic
blood pressure greater than 90 mmHg. A history of previous myocardial
infarction was noted. The study was approved by the local ethics
committee and informed consent was obtained from all participating
patients. Elevated creatine phosphokinase levels were not required prior
to inclusion as there is frequently a delay in obtaining the results from
clinical chemistry which might have reduced the number of eligible
patients. All recruited patients were included in the ISIS-4 pilot study
and randomisation between trial therapies was performed by the ISIS
office in Oxford.
Trial Therapy
Patients (n = 105) were randomised to one of three therapies:- placebo
(n = 36), isosorbide mononitrate 20 mg t.i.d. (n = 33), or captopril
12.5 mg t.i.d. (n = 36). Captopril was initially given as a test dose
6.25 mg and if this was well tolerated the full dose was administered 2
hours later. If patients became hypotensive the protocol permitted
omission of a dose or the use of half a tablet. Blood pressure was
monitored every 15 minutes for the first 2 hours after administration of
the test dose. If the trial medication was tolerated, patients underwent
treatment for 28 days. Patients who were withdrawn and stopped
treatment prior to completing 1 week of trial therapy did not participate
further in the study and therefore did not have assessment of left
ventricular size and function.
Imaging
Left ventricular imaging was performed by three different techniques, so
as to benefit from the strengths of each. Anatomical information was
gained from echocardiography and magnetic resonance imaging whereas
left ventricular systolic function was quantified by radionuclide
ventriculography. The main assessment of left ventricular size and
function was performed at 5 weeks, 1 week after stopping drug
therapy, as it is known that the pharmacological actions of vasodilators
can influence these measurements. This time interval was selected to
eliminate continuing captopril activity, particularly through inhibition of
the tissue angiotensin converting enzyme which may persist for some
days following cessation of therapy (Cohen and Kurz, 1982). This
protocol is in contrast to the original work performed with captopril
where vasodilator therapy was not withdrawn prior to assessment of
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cardiac size and function (Sharpe et al, 1988, Pfeffer et al, 1988).
Echocardiography
Echocardiography was attempted in all patients at 1 and at 5 weeks
after trial entry. Images were recorded on Hewlett-Packard
echocardiogram machines (both sonos 100 and 1000) with the patient
lying semi supine in the semi left lateral position. Where the patient
would comply the recordings were made at end expiration.
Quantification was performed on the short axis parasternal images at
the level of the mitral valve tips (observer: ADH) (figure 1). The
anteroposterior and transverse diameters of the left ventricular cavity
were measured at this level using the Hewlett-Packard calculation
package. The results are reported as the mean diameter (cm).
Radionuclide ventriculography
Left ventricular ejection fraction was assessed by this radionuclide
technique, 5 weeks after study entry. Patients lay supine under a
gamma camera (Siemens LEM) which was positioned in the modified left
anterior oblique position with caudal tilt to provide good ventricular
separation. The camera was interfaced to a Siemen's microdelta
computer. The blood pool was imaged after injection of 700 MBq
Technetium-99m labelled human serum albumin (Miller et al, 1979).
After equilibration, an electrocardiogram gated acquisition of 5 million
counts was made. Ejection fraction was calculated using a semi
automatic technique (Wathen et al, 1990) by two blinded independent
observers (ADH and FT). This technique has an interobserver variation
of 1% and an interstudy variation of 2% (Wathen et al, 1990).
Anterior
Posterior
Figure 1 This diagram represents a frame from an echocardiographic
study - short axis parasternal view at the level of the mitral valve tips.
The internal antero-posterior and transverse diameters were measured
using the Hewlett-Packard calculation package and the mean diameter
was derived.
Magnetic resonance imaging
Patients were scanned approximately 6 weeks following the onset of
chest pain using a low field system (M & D Technology) operating at
0.08 Tesla. A cardiac gating technique was employed to synchronise
data acquisition during end diastole. Six or seven slices of 1 2 mm
thickness and separation were required to obtain short axis views of the
ventricular chambers from the cardiac apex to the outflow tracts. Two
slices with a 32 ms time separation were obtained with each
acquisition, which consisted of two averages of 128 frequency
encoding steps and 64 phase encoding steps resulting in a pixel size of
3x6 mm. This data was interpolated to a 128 x 128 matrix (3x3
mm) and smoothed on the final display monitor for image analysis. A
double spin echo pulse sequence was used with echo delay times (TE)
of 42 and 120 ms for the first and second echoes respectively. The
repetition time (TR) was determined by the patients heart rate but if this
exceeded 95 bpm data was only acquired every other heart beat. The
technical details of the pulse sequence and gating procedure has been
described by Smith et al (1986).
The first echo image routinely provided good anatomical detail with clear
delineation of the endocardial border. To obtain the left ventricular
volume an irregular region of interest was drawn around the endocardial
surface on all slices using image analysis software. The values obtained
were then summed and multiplied by the slice thickness to produce the
total left ventricular volume. Images were quantified by two
independent blinded observers (ADH and LWT) and where there was
disparity the measurements were repeated by both observers together
and a consensus was reached. The interobserver coefficient of variation
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using this technique to measure the volume of infarcted muscle has
previously been measured using this equipment and was reported by
Turnbull et al (1991) to be 10.1%. In addition ventricular wall volumes
were calculated from scans obtained on 3 separate occasions in four
normal healthy volunteers (Turnbull, 1991). Turnbull found the mean
percentage difference in ventricular wall volume measurement was 3%
(range 1.1 % to 7%). The intraobserver variability for 2 observers was
calculated by measuring the same 3 scans on 3 separate occasions and
was 6% and 7% respectively. The interobserver variability between
Turnbull's observers for ventricular wall volume measurements by mean
percentage difference was 14%.
Electrocardiographic analysis
The presence of Q waves and persisting ST elevation was assessed on a
12 lead electrocardiogram performed 24 - 48 hours after the onset of
chest pain. A Q wave was defined as an initial negative deflection of
greater than 0.04 s duration and 2mm magnitude. ST segment
elevation was assessed 0.08s after the J point in the lead with the
maximum upward deviation and was deemed to be significant if it was
greater that 1mm in the inferolateral leads and greater than 2mm in
leads V1 3. Electrocardiographic analysis allowed risk statification of the
study population and a limited sub group analysis.
Statistics
Comparison between groups was performed by the Mann-Whitney U
test for continuous variables and chi-square test for the clinical




The three groups were similar with respect to age, sex, site of infarct
and peak creatine kinase (table 2.1). The distribution of patients with
previous myocardial infarcts was not even (placebo: 4, isosorbide: 4,
captopril: 0). As previous ventricular damage would influence the
observations these patients were not included in the assessment of
either the left ventricle or the clinical outcome. In view of the concern
about the limited and late use of thrombolysis after infarction it is
gratifying to note in this study 88% of patients received thrombolysis
which was initiated early after the onset of chest pain (mean 3.2 hours).
Most patients completed the trial drug therapy.
Reasons for not completing trial therapy (table 2.2)
Eighteen patients did not finish trial medication. Five patients withdrew
consent for participation shortly after entry into the study. One further
patient in the placebo group withdrew himself after 10 days because of
breathlessness, later diagnosed as pulmonary oedema. A minority of
patients were withdrawn for minor symptoms e.g. headache or
indigestion. One patient developed glomerulonephritis attributed to
streptokinase and was withdrawn from trial therapy.
The more serious reasons for withdrawal included reinfarction (1 patient
on captopril) and prolonged hypotension with impaired tissue perfusion
(3 patients all on placebo). Four patients died within the first 28 days.
In the placebo group one died shortly after randomisation and the other
died from cardiac rupture at 4 days. Both patients that died in the
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Continuous variables shown as mean (standard deviation)
TABLE 2.2











No patient appears more than once in this table





Images were recorded from 89 out of the 105 patients. Image quality
precluded quantitative analysis in 17 (19% of those imaged).
Ventricular dimensions were compared in the remaining patients who
had not had previous infarcts (n = 67).
There was no significant difference at 1 or 5 weeks in mean left
ventricular diameter at either end systole or end diastole between the
three treatment groups (figure 2). In no group was there a trend to
dilatation and even patients in the placebo group tended to decrease left
ventricular dimensions during the 4 weeks between studies (table 2.3).
Radionuclide ventriculography
Imaging was performed on 88 patients. Of these 5 were excluded from
analysis because of previous infarction. The 17 patients that were not
imaged had similar baseline characteristics to the remaining 88 patients
except that they had a shorter duration of trial therapy due to
withdrawal (n = 13) or death (n = 4).
The left ventricular ejection fraction at 5 weeks was similar in the three
groups (figure 3). However, the captopril group had fewer patients with
very low ejection fractions (< 20%) (Placebo: 3, Isosorbide: 1,
Captopril: 0).
In a post hoc analysis there was evidence of a beneficial effect on




] 7 DAYS I 5 WEEKS
END SYSTOLE
Trial therapy
Figure 2 Echocardiographic measurement of mean left ventricular
diameter. This histogram shows end-diastolic (top) and end- systolic
(bottom) dimensions in the three trial groups at 7 days (open) and 5
weeks (shaded) (mean + SEM). The numbers in boxes indicate the
number of patients on which the data is based. There is no significant
difference between trial groups.
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TABLE 2.3
DIFFERENCE IN MEAN LEFT VENTRICULAR DIAMETER
BETWEEN 1 AND 5 WEEKS AFTER INFARCTION (cm)
End Diastole End Systole
Placebo -0.25(4-0.15,-0.65) -0.05(4-0.60,-0.50)
Isosorbide -0.10(4-0.35,-0.50) -0.10(4-0.2, -0.48)
Captopril -0.25(4-0.15,-0.55) -0.1 5 (+0.1 5,-0.50)
Footnote
Differences and 95% confidence intervals calculated by Mann Whitney U
test
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Figure 3 Left ventricular ejection fraction at 5 weeks calculated by
radionuclide ventriculography. Each triangle represents 1 patient and
the horizontal bars indicate the mean value for each group. There is no
significant difference between the three groups (n = 88).
95% Confidence intervals for differences between groups
P vs I - 6.5%, + 3.0%
PvsC - 7.0%, + 3.5%
I vs C - 5.5%, + 5.0%
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(particularly isosorbide mononitrate) in the high risk group of patients
with Q waves and persisting ST segment elevation (table 2.4), but
interpretation of this data must be cautious in view of the small number
of patients in each group and the retrospective nature of the analysis.
Magnetic resonance imaging
Fifty six patients underwent magnetic resonance imaging, the number
being limited by machine availability and periods when it was out of
service. Four studies were discarded due to poor image quality and three
were abandoned due to the patient experiencing claustrophobia. The
remaining 49 patients had good quality images that were quantified.
Treatment with vasodilator therapy made no significant difference to the
5 week end diastolic left ventricular volumes (figure 4).
Clinical Outcome
This is an important part of the assessment of the trial therapy as
patients who were withdrawn within the first week of the study do not
appear in the data on ventricular size and function. Table 2.5 shows the
distribution of patients with an adverse outcome. This analysis was
based on an intention to treat and as a history of previous myocardial
infarction would influence outcome, such patients have been excluded.
Two men died and a further two men were withdrawn with cardiogenic
shock in the placebo group. These last two patients had ejection
fractions measured independent of this study and both were less than
20% (16% and 19%). In addition there was one patient in the
isosorbide group who died with cardiogenic shock. These patients
missing from the left ventricular analysis are a potential source of bias
TABLE 2.4
LEFT VENTRICULAR EJECTION FRACTION: SUB GROUP ANALYSIS
Placebo Isosorbide Captopril
Non Q wave infarct
(n = 15) 40.5(10.3) 45.5(6.3) 43.9(10.0)
n = 4 n = 5 n = 6
Q wave Infarct
(n = 68)
No ST elevation 40.6(5.5) 35.6(12.2) 41.4(5.7)
n = 14 n = 10 n = 15
Persisting ST 25.1(9.6) 36.9(8.0)* 32.4(9.6)
elevation n = 7 n = 11 n = 11
Footnote
All patients with past history of myocardial infarction were excluded.
Data shown as mean (standard deviation)
























Figure 4 Scattergram showing left ventricular end diastolic volumes at 5
weeks measured by magnetic resonance imaging. The mean has been
marked by a horizontal bar. There is no significant difference between
the three groups (n=49).
95% Confidence intervals for differences between groups
P vs I - 15.9 ml, + 33.2 ml
P vs C - 11.2 ml, + 28.6 ml
I vs C - 16.6 ml, + 14.5 ml
TABLE 2.5
ASSESSMENT OF ADVERSE OUTCOME
Placebo Isosorbide Captopril




P vs C, p < 0.05 (Chisquared)
Footnote
No patient appears more than once in this table.
All patients with previous Ml have been excluded.
Cardiogenic shock defined as prolonged hypotension with impairment of
perfusion of vital organs without evidence of right ventricular infarction.
and should be borne in mind when interpreting the results. In addition it
is of interest that no patient in the captopril group had such an adverse
outcome. The difference in the clinical outcome between the captopril
and placebo group is statistically significant (p < 0.05).
DISCUSSION
This study has shown no significant improvement in objective measures
of left ventricular size and function from early vasodilator therapy.
However captopril may reduce the number of patients with an adverse
clinical outcome. This result is in contrast to other published studies
reporting the beneficial effect of vasodilator therapy in preventing
ventricular dilatation. Sharpe et al (1988) found that the captopril
treated group increased their ejection fraction by 5% in the first 3
months whereas in the same time period the placebo group suffered a
decrease of 2%. In the study by Pfeffer et al (1988) the left ventricular
end diastolic volume increased in the placebo group by 21 mis in
contrast to only 10 mis in the captopril group. In addition a two hospital
study from Glasgow has recently reported that captopril therapy started
within 24 hours of infarction significantly inhibits ventricular dilatation
(Oldroyd et al, 1991). The captopril treated subjects experienced an
increase in the anterior left ventricular segment length of only 2.8 mm
whereas the placebo treated subjects increased by 10.4 mm. Likewise
intravenous nitrates have proven advantageous as left ventricular
internal end diastolic dimensions increased by 8mm over the first 10
days in the placebo treated patients while there was no significant
change in the dimensions of those that received nitrate (Jugdutt and
Warnica, 1988b). No patient received thrombolysis in 3 of these studies
(Sharpe et al, 1988, Pfeffer et al, 1988, Jugdutt and Warnica, 1988b).
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However the study by Sharpe et al (1991) did include patients treated
with thrombolytic agents , but only if the electrocardiogram showed a Q
wave infarct (Sharpe et al, 1991).
Thrombolysis is likely to have modified the process of ventricular
remodelling by reducing infarct size and by decreasing the frequency of
persisting coronary artery occlusion. Despite the widespread use of
thrombolysis in this study it is relevant that the mean peak creatine
kinase was around 1400U/I and that 78% of the patients developed
pathological Q waves. Only 10 patients proved to have a normal
ejection fraction when assessed 5 weeks after the infarct. This data
indicates that the study population suffered significant myocardial
damage and that the failure of the study to detect a major benefit from
vasodilator therapy does not result from selection of patients with trivial
myocardial infarction.
In this study the placebo group showed no tendency to ventricular
dilatation, instead the mean left ventricular diameter tended to fall over
the 4 week period. This contrasts with the outcome in the placebo
groups of the studies by Sharpe et al (1991), Pfeffer et al (1988) and
Oldroyd et al (1991) which all reported significant increases in the left
ventricular end diastolic dimensions. A likely explanation is that in the
majority of patients receiving thrombolysis there is little tendency to
remodelling and that vasodilator therapy does not produce additional
major benefits in terms of ventricular size and function.
Despite this, vasodilator drugs may have an important role in the
management of patients who are at increased risk of infarct expansion
to
and dilatation. This is borne out from the adverse clinical outcome in
our placebo group in comparison to the captopril treated patients. In
addition there was evidence of a possible beneficial effect of vasodilator
therapy on the subgroup of patients with Q waves and persisting ST
segment elevation. Other workers have identified patients with
persisting ST segment elevation after thrombolysis as having
significantly poorer left ventricular function and a much greater mortality
(Barbash et al, 1990). This study is not the only one to suggest that
benefit from vasodilator therapy after infarction may be limited to a
high risk subgroup. Pfeffer et al (1988) reported a particular benefit
from captopril therapy in those patients with an occluded infarct related
artery. Within this category the placebo group exhibited dilatation with
an increase in end diastolic volume of 31 mis as opposed to an increase
of only 7mls in the group allocated captopril.
This study is small and therefore of limited statistical power, however it
is of similar size to many of the reported studies of captopril therapy
following infarction which range from 60 to 100 patients (Sharpe et al,
1988 and 1991, Pfeffer et al, 1988, Oldroyd et al, 1991). In addition
statistical calculation shows that it is necessary to randomise only 60
patients in order to detect a 5% difference in ejection fraction (assuming
a standard deviation of 12 in the measurements). This study has
demonstrated an important finding that should be considered in
designing larger studies to assess the role of vasodilator therapy. All
patients admitted to a coronary care unit may not benefit from this type
of treatment: in particular, those at low risk of ventricular dilatation
with small infarcts, inferior territory necrosis and with patent infarct
related coronary arteries. In the large multicentre trials (such as ISIS-4) it
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may be important to establish which groups of patients benefit and which
do not.
CHAPTER 3
THE INFLUENCE OF EARLY VASODILATOR
THERAPY ON MYOCARDIAL INFARCT SIZE
AND THE ACUTE INFLAMMATORY RESPONSE
S3
INTRODUCTION
If early vasodilator therapy fails to show a large effect on left ventricular
dilatation, is there a benefit (as hinted by the better clinical outcome in
the captopril group) from other factors. The introduction to this thesis
has already described the postulated activities of captopril and the
nitrate vasodilators to modulate infarct size and the acute inflammatory
response. This chapter details a study that tested for such activity in
the patients that were randomised to captopril, isosorbide mononitrate
or placebo as described in chapter 2. This was possible as trial therapy
was started early after infarction (less than 24 hours after the onset of
chest pain), and therefore at a time when these pathological processes
might be influenced.
Infarct size was measured by a quantitative tomographic radionuclide
technique (Jansen et al, 1985). This method had the advantage of direct
measurement of the volume of infarcted muscle 2 to 4 days after the
onset of chest pain and therefore many hours after starting trial therapy.
Creatine kinase curves were not employed as the peak levels may have
occurred prior to initiating trial therapy, particularly in those who were
not randomised until 24 hours after the onset of chest pain. In addition
the interpretation of enzyme release curves is influenced by
thrombolysis as reperfusion is associated with an earlier and often
greater peak level.
Two aspects of the acute inflammatory response were assessed-
neutrophil activation and free radical activity. Neutrophil activation was
quantified using a specific radioimmunoassay for plasma neutrophil
elastase (Plow, 1982). As neutrophil elastase is normally found in the
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azurophilic neutrophil granules, elevated plasma levels reflect
degranulation and the release of enzyme that is associated with
activation. It is a reliable indicator of activation that can be readily
applied to a large number of samples. In contrast some workers have
employed an indirect elastase assay which measures the concentration
of peptide Bft a product of fibrin(ogen) degradation by elastase (Mehta
et al, 1989), but data interpretation is potentially complicated by
variations in substrate and inhibitor concentrations. A futher approach
involves measuring the changes in the flow properties of leucocytes.
The ability of leucocytes to pass through a filter in response to a
pressure gradient (filterability) decreases with activation. Although
diminished filterability correlates well with histological features of
activation (Nash et al, 1989), it is a time consuming and again an
indirect measure.
The measurement of free radical activity is complicated in vivo and has
been discussed at length in the introduction. In this study free radical
attack on phospholipid linoleic acid was assayed using high performance
liquid chromatography to detect conjugated dienes (Iversen et al, 1985).
This index has previously been shown to be elevated after infarction
(Bell et al, 1990).
METHODS
Patients
The one hundred and five patients that were randomised in the study
described in chapter 2 were eligible for this investigation. Patients were
excluded if they were withdrawn from the study within the first 48
hours after randomisation (13 patients: 6 patients withdrew consent in
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this period, 1 reinfarcted, 3 had significant hypotension and 3 died). All
gave informed consent and the study was approved by the local ethics
committee.
Trial therapy
As described in chapter 2 patients were randomised in double blind
fashion to one of three treatment groups: double placebo tablets three
times daily; isosorbide mononitrate 20 mg three times daily and captopril
placebo; or captopril 12.5 mg three times daily with isosorbide placebo.
The captopril group received a test dose of active captopril 6.25 mg two
hours before starting the full dose regime (the other two groups received
a test dose of placebo).
Infarct size
Quantitative radionuclide infarct imaging was performed between 2 and
4 days following the onset of pain and at least 24 hours after entry into
the study. Imaging was not carried out in 27 patients because of
withdrawal from the study (n = 12), mechanical breakdown (n = 5)
and entry into the study before ethical approval for radionuclide imaging
had been obtained (n = 10). There was no difference in the baseline
characteristics between those who underwent imaging and those who
did not.
Two hours prior to imaging, 400 MBq technetium 99m labelled
pyrophosphate was injected intravenously. Single photon emission
computed tomographic imaging was performed over 360° with 64
images being acquired, each over 10 seconds using a IGE 400 AT
maxicamera linked to a Siemens Microdelta computer. Transverse
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images were reconstructed by backprojection using a Butterworth filter
after correction for centre of rotation and non-uniformity. The images
were smoothed twice. The volume of infarcted muscle was measured
using a semiautomatic technique that counted the number of voxels
with values greater than 65% of peak myocardial uptake (Jansen et al,
1985). One voxel has a volume of 0.24 ml and the results in this
chapter are reported in millilitres. It has been shown that this in vivo
technique correlates closely with infarct size as judged from increased
T1 relaxation parameter on magnetic resonance imaging (Turnbull et al,
1991). Images were quantified by two independent observers (ADH and
FT). The coefficient of variation between observers was 6.4% and for
the same observer was 4.7%. Figures 5 and 6 show examples of an
inferior infarct and an anterior infarct with the region of interest drawn
around the infarcted area.
Acute inflammatory response
Assessment was by peripheral blood sampling immediately prior to
initiating trial therapy and at 6, 12, 18, 24, 36 and 48 hours after the
first dose. These times were selected as Bell et al (1990) had already
shown that there was evidence of acute inflammatory activation over
this period.
a) Plasma neutrophil elastase
Venous blood (5ml) was taken into sodium citrate in HEPES buffer.
Plasma was separated in a cooled centrifuge (4°C) and stored at -20°C.
Only the top 1 ml of plasma was used for analysis to avoid
contamination from the buffy coat.
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Figure 5 A transverse tomographic image of a patient with an acute
anterior myocardial infarct after injection with technetium-99m
pyrophosphate. Note the horseshoe shape of the infarcted myocardium.
The box has been positioned around the area of infarction to permit
quantification.
Figure 6 A transverse tomographic image of a patient with an acute
inferior myocardial infarct after injection with technetium-99m
pyrophosphate. In this image the infarct appears flat like a pancake as
the inferior wall lies in the same plane as the slice.
The plasma neutrophil elastase concentration was measured by specific
radioimmunoassay with rabbit polyclonal antiserum (Plow, 1982).
Purified human neutrophil elastase was obtained from Calbiochem via
Novabiochem, Nottingham, UK. The antibody was specific for
neutrophil elastase - measuring both free enzyme and that bound to its
natural inhibitors. The results are expressed as ng/ml. The intra-assay
coefficient of variation was <5% (Bell et al, 1990).
b) Diene molar ratio
A 5 ml sample of blood was drawn into a lithium heparin tube. Plasma
was separated in a cooled centrifuge (4°C) and stored at -20°C. The
molar concentrations of two isomers of linoleic acid (18:2) were
measured in the phospholipid fraction. The native isomer of linoleic acid
has double bonds at the 9 and 12 positions (18:2 (9, 12)). Free
radical attack can result in isomerisation of this molecule so that the
second double bond moves to the 11 position (18:2 (9, 11)) (figure 7).
In this form it is said to be a conjugated diene (2 double bonds
separated by only one single bond). The measurement of these isomers
was performed using high performance liquid chromatography in plasma
after enzymatic hydrolysis with phospholipase A2 and solid phase
sample preparation (Iversen et al, 1985). The results are expressed as
the molar ratio of 18:2 (9, 11) to 18:2 (9, 12). The ratio increases in the
presence of free radical lipid attack. An internal standard (cis 9,11
linoleic acid) was used to compensate for variable loss of sample during
the preparation and analysis. The intra-assay coefficient of variation was
<3.5%.
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Figure 7 This diagram shows the two isomers of linoleic acid (18:2) and
the chemical reaction with free radicals that can result in the
isomerisation of 18:2(9,1 2) to 18:2(9,11).
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achieved in 83 patients and of diene molar ratios in 82 patients.
The remaining patients were excluded either because they had
withdrawn from the study within the first 48 hours (n = 12) or the
samples were either haemolysed or damaged. There was no difference
in the baseline characteristics between those that did and those that did
not have satisfactory sampling.
Statistics
The effects of trial therapy on infarct size and the acute inflammatory
response were analysed using the non-parametric Mann Whitney U test
(Minitab, release 6.1, PA, USA). Values of p < 0.05 were taken as
significant. The significance of the change in plasma markers over the




The three groups were well matched at baseline being similar with
respect to age, site of infarction, infarct size and time to trial entry (see
chapter 2, table 2.1). The initial plasma neutrophil elastase levels (table
3.1) and diene molar ratios (table 3.2) were also similar between
the groups.
Plasma neutrophil elastase
Figure 8 shows the plasma neutrophil elastase values in the three groups
at various time intervals after the onset of chest pain. Peak levels
occurred between 18 and 24 hours after the onset of pain. The peak
and average plasma neutrophil elastase levels were elevated in all three
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TABLE 3.1
PLASMA NEUTROPHIL ELASTASE LEVELS (ng/ml) IN RELATION
TO VASODILATOR THERAPY (MEAN _+ SD)
Placebo Isosorbide Captooril
n = 28 n = 29 n = 26
Pre-therapy 40.2(16.5) 53.5(26.2) 45.0(18.0)
Post therapy -
peak 69.4(53.6) 98.7(84.2) 62.1(24.0)
Post therapy -
average 39.0(18.9) 52.3(28.5) 41.6(12.8)
Footnote
Normal laboratory values: median 18.6 ng/ml (range 9.2-51)
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TABLE 3.2
DIEIME MOLAR RATIOS (x 100) IN RELATION
TO VASODILATOR THERAPY (MEAN _±_ SD)
Placebo Nitrate Captopril
n = 26 n = 27 n = 29
Pre therapy 3.27(1.53) 3.50(1.38) 3.33(1.87)
Post therapy -
peak 3.64(1.72) 3.78(1.45) 3.67(1.83)
Post therapy -
average 2.80(1.12) 2.96(1.11) 2.92(1.43)
Footnote
Normal laboratory range: median 1.26 (range 0.94-3.03)
Plasma neutrophil elastase (ng/ml)
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Figure 8 Plasma neutrophil elastase concentrations in 83 patients with
acute myocardial infarction with the data (mean _+_ SEM) displayed
according to the time after the onset of chest pain. The elastase
concentrations are elevated above normal but they are not influenced by
early treatment with either captopril or isosorbide mononitrate.
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groups (normal laboratory values: median = 18.6 ng/ml, range 9.2 -
51.0), but there were no significant differences between any of the
treatment groups (table 3.1 and figure 8).
Diene molar ratios
Figure 9 shows the sequential changes in the conjugated diene levels in
the three treatment groups after the onset of pain. The peak and
average diene molar ratios were also substantially elevated
following myocardial infarction (normal laboratory values: median =
1.26, range 0.94- 3.03) (table 3.2). Peak levels occurred at around 18
hours after the onset of chest pain and there was a significant fall in the
diene levels with time up to 72 hours (analysis of variance, p < 0.05).
Vasodilator therapy did not influence the diene molar ratio (table 3.2 and
figure 9).
There was no correlation between plasma neutrophil elastase
concentrations and the diene molar ratio. There was a weak
correlation between peak creatine kinase levels and both the average
plasma neutrophil elastase concentration and the diene molar ratio
(r = 0.25 and 0.23 respectively, both p < 0.05).
Pyrophosphate infarct sizing
Infarct size varied from very small with no significant uptake to
extensive infarcts involving much of the myocardium (figure 10). In 9
patients myocardial uptake was diffuse and so quantification of the
infarct size by this technique was not possible. The images from the
remaining 69 patients were quantified. There were no significant
differences in infarct size between any of the groups (figure 10).
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Figure 9 The diene molar ratios (9,11 linoleic acid/ 9,12 linoleic acid) in
82 patients with acute myocardial infarction at various time points after
the onset of chest pain (mean _+_ SEM) . Peak levels were found at 18
hours and there was a significant fall thereafter (p < 0.05). Therapy






























Figure 10 Myocardial infarct size in the 3 trial groups as measured by
quantitative tomographic Technetium 99m pyrophosphate imaging in 69
patients. There was no evidence of infarct size modification by
vasodilator therapy with either captopril or isosorbide mononitrate.
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DISCUSSION
Vasodilator therapy did not modify infarct size in this study. The effect
of captopril on infarct size has not previously been assessed in man,
but the results of animal studies are conflicting. Ertl et al (1982)
reported the beneficial effects of early captopril treatment in an animal
model of infarction involving permanent coronary artery occlusion
without reperfusion. In a different experimental design, intravenous
captopril was given to pigs during a one hour coronary artery occlusion
and afterwards during a period of reperfusion producing a dose
dependent reduction in myocardial damage (De Graeff et al, 1987).
However Liang et al (1982) and Daniell et al (1984) found that captopril
did not influence infarct size even when treatment was started 10
minutes after coronary ligation.
Intravenous nitroglycerin has also been reported to reduce myocyte
damage in a study of 310 patients with acute infarction (Jugdutt and
Warnica, 1988b). Creatine kinase curve analysis showed infarct size to
be significantly less in the treated group, particularly when nitroglycerin
was started within 11 hours of the onset of pain. In addition animal
investigation has shown that nitroglycerin therapy reduces infarct size
after coronary occlusion. Intravenous nitroglycerin reduced infarct size in
dogs from 12.1% of the left ventricle to 6.4% as assessed 48 hours
after occlusion by histological examination (Jugdutt et al, 1981). In a
later study, Jugdutt (1985) reported that infarct size was reduced to
less than a third of that in control dogs when assessment was delayed
until one week after infarction. In addition in this study he showed that
there was no detrimental effect on healing and scar formation.
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The human study reported in this chapter differs from the previous work
as it involves oral medication, initiated 15 hours (mean time) after the
onset of chest pain to a group of patients that have largely received
thrombolytic therapy. Earlier intravenous administration with larger
doses of vasodilators would have been preferable in order to directly
compare clinical infarction with the animal models. The main concern of
such intervention would be hypotension.
Excessive falls in blood pressure to a mean arterial pressure less than 80
mmHg resulted in significantly larger infarcts in the study of intravenous
nitroglycerin reported by Jugdutt and Warnica (1988b). Those with drug
induced hypotension had a greater mean infarct size (81.3 gram
equivalents (geq)) than a similarly hypotensive control group (65.4 geq).
The CONSENSUS II trial showed an increased mortality in those
experiencing hypotension after vasodilator therapy (with a systolic blood
pressure less than 90 mmHg or diastolic less than 50 mmHg) (Swedberg
et al, 1992). The six month mortality was 17% among patients who
were hypotensive after enalapril therapy and only 12% among patients
who had similar hypotension after placebo. A detrimental fall in blood
pressure may have been precipitated by the initial dose of vasodilator
being given intravenously as enalaprilat and so inducing a sudden
change in the coronary perfusion pressure. Indeed it is relevant that the
CONSENSUS II study failed to show a benefit from early vasodilator
therapy. A deleterious effect of low blood pressure was also evident in
an animal model of infarction used to study intravenous nitroglycerin
(Jugdutt, 1983). As thrombolysis per se reduces blood pressure, it is
probably desirable to delay initiating vasodilator therapy until after such
too
intervention unless absolutely necessary. Indeed in most clinical studies,
captopril therapy was not given until at least 24 hours after the onset of
pain (Sharpe et al, 1988, Pfeffer et al, 1988, Sharpe et al, 1991).
This work confirms previous reports of free radical activity following
myocardial infarction (Bell et al, 1990, Davies et al, 1990a). Like the
work of Bell et al (1990) the diene molar ratio was highest 12-18 hours
after the onset of pain. There was a steady fall in the ratio after 24
hours towards normal levels at 72 hours. The results in this chapter
were based on samples taken after randomisation and not immediately
on admission to hospital or even prior to thrombolysis. Thus it is not
possible to comment on the very early hours after the onset of chest
pain or the effect of reperfusion. The exact source of the free radicals
causing isomerisation of linoleic acid is not clear. There is considerable
animal experimental data (reviewed in the introduction) that indicates
that reperfusion after a period of ischaemia results in free radical
activity. The next chapter of this thesis specifically addresses this issue
employing two markers of free radical activity, conjugated dienes and
plasma vitamin C concentrations. The lack of correlation between
plasma neutrophil elastase concentrations and the diene molar ratios
makes it less likely that activated neutrophils and the stimulated
inflammatory response are the main source of the lipid attacking free
radicals. Free radicals and their reaction products may be released from
dying and necrotic cells and therefore may partly explain the weak
correlation between peak creatine kinase levels and diene molar ratios.
Neutrophil activation resulting in elastase release occurs early after
myocardial infarction (Mehta et al, 1989; Bell et al, 1990). The data in
this chapter confirms this showing peak values 18 to 24 hours after the
onset of pain and a trend to decreasing levels over the following 48
hours. The early peak in elastase concentrations confirms the
importance of neutrophil activation in this initial period and agrees with
the observation by Bell et al (1987) that radionuclide labelled neutrophils
must be reinjected within 24 hours of infarction in order to see reliable
myocardial uptake. The standard deviation of the early values is much
greater than that of the later measurements. This was also evident in a
similar study by Bell et al (1990) that compared patients treated with
and without thrombolysis. The large standard deviation is caused by
some patients exhibiting a markedly elevated elastase concentration. It
is not clear why this occurs. The very early inflammatory response and
its interaction with thrombolysis is the topic of the next chapter.
Vasodilator therapy with captopril, had no effect on free radical activity.
This differs from animal and isolated heart studies that have shown free
radical scavenging by this drug when used in high dose (5 mg/kg)
(Westlin and Mullane, 1988, Bagchi et al, 1989b). As discussed above
hypotension is a concern early after infarction and this very high dose is
unacceptable for use in man so soon after infarction if ever. The dose of
captopril used in this study (37.5 mg daily) was small compared to that
in the laboratory studies, although not without haemodynamic effects
(Flather et al, 1991). The length of time between onset of ischaemic
damage and treatment may be an additional explanation of the differing
results between animal studies and man as our therapy was started
some hours after the onset of chest pain and any attempts to induce
reperfusion.
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In this study neither captopril nor nitrate therapy influenced plasma
neutrophil elastase concentrations. This is perhaps surprising given the
known anti- inflammatory effects of captopril and the proinflammatory
effect of angiotensin II that were reviewed in the introduction. There
have been no previous clinical studies addressing this question in
myocardial infarction. Modification of the inflammatory response does
not appear to be an important action of vasodilators in myocardial
infarction in man, at least using this regime of administration.
This study has demonstrated the lack of influence of early oral therapy
with captopril or nitrate on both infarct size and the acute inflammatory
response to infarction. In previous clinical studies captopril prevented
progressive ventricular dilatation after infarction (ventricular remodelling)
even when therapy was not introduced until up to 4 weeks after
infarction (Sharpe et al, 1988, Pfeffer et al, 1988). In addition animal
investigation has indicated that captopril is equally effective in limiting
ventricular dilatation after coronary occlusion whether initiated within 2
days or 3 weeks after the coronary ligation (Gay, 1990). This study
therefore provides circumstantial evidence that prevention of the
mechanical process of ventricular remodelling may be the most
important action of vasodilator therapy after infarction. The optimum
timing for the initiation of such therapy remains to be elucidated, but
may not need to be introduced until the patient is stable and the risk of
precipitous hypotension is decreased.
CHAPTER 4
THE EFFECT OF STREPTOKINASE ON THE




Ischaemic myocardial necrosis stimulates an acute inflammatory
response which in turn may increase the extent of necrosis and infarct
size. Animal studies (reviewed in the introduction) indicate that free
radicals, the complement pathways and neutrophils may mediate such
injury. It is not clear if thrombolytic therapy with streptokinase may
have advantageous or deleterious interactions with this inflammatory
response.
Streptokinase may provoke an inflammatory response as a reaction to
coronary reperfusion. There is considerable evidence from animal studies
that reperfusion injury exists (reviewed in the introduction). Although
myocyte injury from reperfusion has never been demonstrated in man,
there is circumstantial evidence to suggest that it may occur. Davies et
al (1990a) found elevated levels of malondialdehyde in those with
angiographic evidence of reperfusion. Neutrophil activation is evident 2
hours after streptokinase therapy in those that reperfuse (Ranjadayalan
et al, 1991) but the early time course of this process has not been
defined. Bell et al (1990) found higher concentrations of plasma
neutrophil elastase in those patients that had received streptokinase
post infarction. A temporal relationship between reperfusion and
systemic markers of the acute inflammatory response would provide
further circumstantial evidence that such injury might be occurring.
Interactions may occur between streptokinase and the mediators of
acute inflammation independent of reperfusion. Firstly, streptokinase is a
foreign protein and capable of reacting with anti-streptokinase
antibodies that are present in the majority of individuals. In a study of
/or
93 normal volunteers all were found to have IgG anti-streptokinase
antibodies (Moran et al, 1984). Indeed type I and III hypersensitivity
reactions are well recognised complications of this therapy (GISSI,
1986). Secondly, plasmin is produced in large quantities by the
streptokinase-plasminogen complex and this powerful protease may
partly activate the complement pathways through direct cleavage of
complement components. This reaction has at least been demonstrated
in vitro (Ratnoff and Naff, 1967; Taylor and Ward, 1967). Stimulation of
the acute inflammatory response by these mechanisms might be
detrimental by increasing the degree of neutrophil activation or might be
advantageous if a state of relative complement depletion occurred prior
to reperfusion.
This chapter describes a study that investigated the time course of the
acute inflammatory response in a group of patients that received
standard intravenous streptokinase therapy. In view of the risks of
coronary angiography early after thrombolytic therapy, a non invasive
technique involving ST segment analysis was employed to differentiate
those with successful and unsuccessful thrombolysis (Hogg et al,
1988). Free radical activity was measured indirectly by quantification of
both plasma conjugated diene levels (Iversen et al, 1985) and plasma
ascorbic acid concentrations (Vuilleumier and Keck, 1989). Detailed
analysis of the complement pathways was undertaken measuring total
activity and the concentrations of individual factors, anaphylatoxins and
multimolecular complement activation complexes (Kent and Fife, 1963;
Platts-Mills and Ishizaka, 1974; Phimister and Whaley, 1990). Plasma
neutrophil elastase levels were analysed to evaluate the extent of




Seventeen patients were recruited. All were admitted to the coronary
care unit with acute myocardial infarction (typical chest pain and ST
elevation) and were prescribed intravenous streptokinase 1.5MU by the
responsible physician. Subsequent cardiac enzyme analysis confirmed
the clinical diagnosis in all patients. The local ethics committee approved
the study and all patients gave informed consent.
Blood sampling
Two intravenous cannulae were inserted - one into each arm. The first
was used to deliver the streptokinase infusion and the second was used
for repeated blood sampling. 5mls blood was drawn and discarded prior
to each sample to ensure full evacuation of the dead space. The cannula
was flushed with 5mls N saline after sampling to prevent obstruction by
thrombus. Blood was removed prior to therapy with streptokinase and
20, 45, 75 and 120 min after initiating treatment.
Conjugated dienes
5mls blood was drawn into a lithium heparin tube (Sterilin) and was
spun at 4°C for 10min at 2500rpm. The supernatant was removed and
stored at -20°C. The concentration of the conjugated diene of linoleic
acid ((18:2) 9,11) in the phospholipid fraction was measured by the
method of Iversen et al (1985) (described in chapter 3) and the result





Blood (5mls) was taken into a tube with potassium ethylene diamine
tetraacetic acid (EDTA) anticoagulant and 560 iu Aprotinin (Trasylol,
Bayer). Plasma was separated by centrifugation at 2500rpm at 4°C for
10mins. 1ml plasma was added to 1ml 5% metaphosphoric acid before
storing the mixture at -70°C prior to analysis. The stock metaphosphoric
acid solution was renewed and filtered once a month. Ascorbic acid
concentrations were assayed by the method of Vuilleumier and Keck
(1989). This depends on enzymatic oxidation of ascorbic acid by
ascorbate oxidase and the subsequent generation of quinoxaline from
the reaction of dehydroascorbate and 1,2 phenylene diamine to produce
fluoresence. The assay was performed on the Cobas-Bio centrifugal
analyser. The relationship between fluorescence and the ascorbate
concentration was linear up to 200 micromol/l. The assay had a
coefficient of variation of 2.7%.
Complement
A further 10mls blood was used for the complement analyses. Half was
anticoagulated with potassium EDTA and 560iu aprotinin and half was
allowed to clot in a glass tube. It was established that aprotinin did not
interfere with the analyses. The concentration of aprotinin was
sufficient to inhibit in vitro plasmin production as there was no evidence
of complement activation in pre-therapy samples that were spiked with
1 500U streptokinase (Kabikinase, Kabi). Plasma, separated by spinning
at 2500rpm at 4°C for 10 min, was split into 3 aliquots and stored at
-70°C. Serum was pipetted from the glass tube without anticoagulant
after clotting and was stored in 3 aliquots at -70°C.
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The total haemolytic titration (CH50) was performed using serial
dilutions of test serum in conjunction with anti-erythrocyte antibody
sensitised erythrocytes according to the method of Kent and Fife
(1963). The alternative pathway haemolytic complement titration was
also performed using serial dilutions but with unsensitized rabbit
erythrocytes which are known to activate the alternative pathway. The
method has been described by Platts-Mills and Ishizaka (1974). The
levels of individual complement factors were measured by nephelometry
with high affinity, monospecific antibodies for C3, C4, Factor B (Atlantic
antibodies) and C1 inhibitor (Scottish Antibody Production Unit, Law
Hospital, Lanark) (Phimister and Whaley, 1990). The coefficient of
variation for the measurement of factor concentrations by nephelometry
was 10%. Anaphylatoxin (C3a, C4a, C5a) concentrations were assayed
using commercial radioimmunoassays employing specific antisera and
I125 labelled ligand (Human complement C3a/C4a/C5a des arg (I125)
assay systems, Amersham International PLC, Aylesbury). A second
antibody was used to precipitate the antibody ligand complexes. The
limit of sensitivity was 40ng/ml for C3a, 80ng/ml for C4a and 12ng/ml
for C5a. The coefficient of variation was 15%. The concentrations of
multimolecular complement activation complexes were quantified using
a sandwich enzyme linked immuno adsorbent assay (ELISA). This
depends upon the use of two antibodies that have specificity for the
activation products of two different components of the complex. The
first or "capture" antibody is fixed to a microtitre plate and the second
antibody is labelled to permit detection of the complex. The
methodology has been described by Phimister and Whaley (1990). The
coefficient of variation was 15%. The complexes assessed were
C1r:C1s:C1-inhibitor reflecting classical pathway activation, C3bBbP
which is produced by activation of both pathways and C5b-9 complex
which indicates terminal pathway activation (see fig 11).
Plasma neutrophil elastase
Using an identical protocol to that described in chapter 3, 5mls venous
blood was drawn into sodium citrate with HEPES buffer, before plasma
separation. Once again the anticoagulant contained 560 iu aprotinin to
prevent in vitro generation of plasmin and possible artefactual neutrophil
activation. It was established that aprotinin did not interfere with the
elastase assay. The plasma neutrophil elastase concentration was
measured by the method of Plow (1982).
Electrocardiographic analysis
Twelve lead electrocardiograms (ECG) were recorded prior to and two
hours after initiating the streptokinase infusion. ST elevation, measured
0.08s after the J point, was quantified using the PR segment as a
baseline. In accordance with the work of Hogg et al (1988) a change of
50% or more in the lead with the maximum initial ST elevation indicated
successful reperfusion. For analysis the study group was split into two
groups: those with and those without ECG evidence of reperfusion.
Statistic
Groups were compared using the non parametric Mann-Whitney U test
for continuous variables and the chi squared test for frequencies of
characteristics. Differences in the response to streptokinase were
assessed by calculating the area under the curve for each subject
(corrected for baseline values). The areas for the reperfused and non-




Figure 11 This diagram illustrates the complement pathways. Classical
pathway activation generates the complex C1r:C1s:C1 inhibitor.
Activation by either pathway causes the formation of the C3
convertase: C3bBbP. Terminal pathway activation is evident by the
production of the C5b-9 complex.
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were performed by Minitab release 6.1 (Minitab, PA).
RESULTS
Baseline characteristics
The two groups were similar with respect to age, sex, time to
thrombolytic therapy and peak creatine kinase (table 4.1). In addition
the initial blood pressure and ST segment elevation were comparable
(table 4.2 and 4.3). The reperfused group included 6 cases of anterior
infarction whereas there were no cases of infarction in this territory in
the non-reperfused group.
Blood pressure response (table 4.2)
Both groups suffered similar decreases in systolic and diastolic blood
pressure.
Free radical activity
There was no relationship between the duration of chest pain and the
initial blood levels of either ascorbic acid or the diene molar ratio (table
4.4). However, even prior to streptokinase treatment the non-reperfused
group tended to have higher levels of ascorbic acid and lower levels of
the diene molar ratio, suggesting that these patients might have been
exposed to less free radical activity than the reperfused group (figure
12). Neither streptokinase nor reperfusion modified the level of free
radical activity as indicated by plasma ascorbic acid concentrations or
the diene molar ratio (figure 12).
Complement





n = 12 n = 5
Age (years) 59.5(11.2) 64.6(6.2)
Smokers 9 2
Previous Ml 2 1
Diabetes 0 1
Site (Ant:lnf) 6:6 0:5







Data presented as mean (standard deviation)
TABLE 4.2




















Data presented as mean (standard deviation)
TABLE 4.3
ST SEGMENT ELEVATION (mm)
Reperfusion Non reperfused
n = 12 n = 5
Pre therapy
Lead with maximum 5.1(3.0) 3.4(1.7)
Total 23.6(15.7) 21.2(10.6)
Post therapy
Lead with maximum 1.3(1.0) 2.5(0.9)
Total 7(6.2) 14.9(4.2)
Footnote
All data presented as mean (standard deviation)
TABLE 4.4
RELATIONSHIP BETWEEN INFLAMMATORY MARKERS AND THE


















































Sol C5b-9 (ng/ml) 5.7 2-69 -.34
Footnote
No parameter had a significant correlation between pre-therapy value
























20 40 60 80 100 120
Time (min)
Figure 12 The top graph shows the change in the diene molar ratio with
time over the 2 hours after starting streptokinase therapy. There was no
significant change in either group. The non reperfused patients (n = 5)
tended to have a lower level than the reperfused patients (n = 12). The
bottom graph illustrates the change in plasma vitamin C levels over the
same time period. The vitamin C levels did not change in either group of
patients. The non reperfused patients tended to have a greater vitamin C
level and may reflect a lower preceding level of free radical activity.
Mean ± SEM. The fine dotted lines represent the reference range (upper
limit for diene molar ratio and lower limit for vitamin C).
//7
therapy and initial levels were not influenced by the duration of
preceding ischaemia (table 4.4). The non-reperfused group suffered a
rapid and significant depletion of complement haemolytic capacity, with
a fall in classical pathway CH50 from 20 min onwards (p<0.05) (figure
13). There was also a tendency for the alternative pathway CH50 to fall
in the non-reperfused group but this failed to reach significance (data
not shown). In addition there was an increase in the concentration of
the C3b:Bb:P complex at the same time (comparing the 20 minute levels
in the two groups, p<0.02) (figure 14). This occurred without a
reduction in the systemic levels of C3, C4, Factor B and C1-inhibitor, at
least as detected by these antibodies (figures 15 and 16). Neither was
there an increase in C1 r:C1 s:C1-inhibitor complex or C5b-9 complex
during this period (figure 17). The patients that did reperfuse did not
have evidence of significant complement activation either during or after
streptokinase infusion, although there was still a minimal but transient
rise in C3b:Bb:P levels detected 20 min after initiating therapy (figure
14). Anaphylatoxin levels rose rapidly after initiating streptokinase
therapy and remained high in both groups. This tended to be greater in
the patients that did not reperfuse (C3a: p = 0.15; C4a: P = 0.31) (figure
18). Anaphylatoxin release was limited to C3a and C4a. C5a levels
remained low over the 2 hour period in all cases irrespective of perfusion
status (data not shown).
Neutrophil elastase
Baseline levels of plasma neutrophil elastase were normal in both groups
before thrombolysis and there was no trend to increased activity in
cases which had experienced chest pain for longer (table 4.4). In the
non-reperfused group neutrophil activation was dramatic and rapid in
n%
Time (min)
Figure 13 This figure depicts the time course of changes in complement
functional activity (CH50) over the 2 hours after starting streptokinase
therapy. The non reperfused patients (n = 3) exhibited a marked
reduction in activity in comparison to the reperfused patients (n = 9)
(p<0.05) . Data only available on 12 patients for this parameter. Mean
± SEM. The fine dotted lines represent the reference range.
Time (min)
Figure 14 The time course of changes in C3bBbP complex
concentrations in plasma after streptokinase infusion. The 20 minute
levels are significantly greater in the non reperfused group (n = 5) than
the reperfused group (n = 12) (p<0.02). Mean ± SEM. The fine clotted
lines represent the reference range.
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Figure 15 This figure illustrates the lack of change in the concentrations
of either total C3 (above) or total C4 (below) in both the reperfused
patients (n = 12) and the non reperfused patients (n = 5) after
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Figure 16. These graphs show factor B (above) and C1 -inhibitor (below)
levels plotted against time after the initiation of streptokinase therapy in
patients who reperfused (n = 12) and those who did not reperfuse
(n = 5). There was no significant change in either group. Mean ± SEM.
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Figure 17. Both these graphs represent changes in the concentrations of
multimolecular complexes following streptokinase therapy. There was
no change in the level of C1r:C1s:C1 inhibitor in either the reperfused
(n = 12) or non reperfused groups (n = 5). In a similar fashion the level of
C5b-9 remained low in both groups. Mean ± SEM. The fine dotted lines




Figure 18. This figure shows the changes in the anaphylatoxin levels
after initiation of streptokinase therapy. There is a brisk rise in the level
of C3a within the first 20 min. This tended to be greater in the patients
without reperfusion (n = 5) than those with reperfusion (n = 12)
(p = 0.15). A similar pattern was observed when the C4a levels were
measured and once more the non reperfused patients tended to higher
values (p = .31). Mean ± SEM. The fine dotted lines represent the
reference range.
3/5 cases, starting less than 20 min after thrombolytic therapy (figure
19). In contrast the elastase concentrations tended to rise less in the
reperfused group (p=0.07) and largely after 45 min, when reperfusion
was likely to have occurred after streptokinase therapy.
DISCUSSION
This study demonstrated that complement activation occurred early
after starting streptokinase therapy with increased production of the
complex C3b:Bb:P and the anaphylatoxins, C3a and C4a. C3b:Bb:P
concentrations were significantly greater in those without reperfusion, in
whom there was also early neutrophil activation with marked elevation
of plasma neutrophil elastase. The increase in anaphylatoxin levels did
not differ significantly between the groups. It is relevant that
C1 r:C1 s:C1 -inhibitor complexes were not detected as would be
expected in a classical antigen-antibody reaction and neither did the
levels of soluble C5b-9 complexes or C5a fragments rise which would
normally increase with full terminal pathway activation.
The most likely cause of this complement activity is the proteolytic
action of plasmin generated by streptokinase plasminogen complexes.
Firstly, it is unlikely to be secondary to reperfusion as complement
activity is seen early after initiating therapy. Very few arteries regain
patency within the first 20 minutes of treatment. In phase I of the TIMI
trial only 8% of arteries were patent in the streptokinase group 20
minutes after starting intravenous streptokinase (Chesebro et al, 1987).
Indeed most successful reperfusion occurred later than 45 minutes after
starting therapy. Secondly, the production of C3b:Bb:P without
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Figure 19 This graph shows the plasma neutrophil elastase
concentrations in the two groups over the two hours after streptokinase
administration. The non-reperfused patients (n = 5) tended to a more
rapid and greater elevation in plasma neutrophil elastase levels than the
reperfused group (n = 12) (p = 0.07). Mean ± SEM. The fine dotted line
shows the upper limit of the reference range.
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antibody mediated mechanism. This is emphasised by the results from
an opportunistic positive control - a patient with active rheumatoid
arthritis. She was not given streptokinase but had elevated levels of
C1s:C1r:C1-inhibitor complex (79ng/ml), C3BbP complex (137ng/ml)
and soluble C5b-9 complex (>200ng/ml). It is well known that
complement activation in this disease is related to antigen-antibody
reactions. The lack of a decrease in the concentrations of total C3, C4,
factor B and C1 -inhibitor after streptokinase does not mean that they
have not been modified by plasmin. The specific antibodies employed
may simply continue to recognise the cleaved product as well as the
native factor. Indeed the anaphylatoxin assays demonstrated that
significant quantities of peptide fragments were generated in all
patients. Perhaps in the non reperfusion group the cleavage products are
capable of generating a C3 convertase and so provoking fluid phase
complement activation and consumption. In agreement with this theory
the increase in C3a concentrations tended to be greater in the non-
reperfused group. In addition the functional assays confirmed that
complement activity was markedly impaired in those that do not
reperfuse. Thirdly, recombinant tissue plasminogen activator, another
agent capable of generating plasmin, has been shown to trigger a rise in
plasma levels of the anaphylatoxins, C3a, C4a and C5a, within minutes
of starting the infusion when used in patients with acute myocardial
infarction (Bennett et al, 1987). Unlike streptokinase this agent is not
antigenic and therefore the chances of an antigen-antibody reaction are
remote. The total levels of C3 and C4 were also measured in their study
and remained unchanged during thrombolysis. Unfortunately
complement functional activity or multimolecular complexes were not
assessed.
Ill
An alternative explanation for complement activation after streptokinase
could be a low grade antigen-antibody reaction sufficient to stimulate
fluid phase amplification by the alternative pathway. Moran et al (1984)
have shown that IgG anti-streptokinase antibodies were universally
present in normal subjects. Although there is some evidence that anti-
streptokinase antibodies can influence reperfusion, their pre-therapy IgG
levels do not correlate with successful thrombolysis (Gemmill et al,
1990). There is a relationship between reperfusion and the development
of a systemic lytic state, defined as a low plasma fibrinogen
concentration after thrombolysis. Brugemann et al (1990) reported that
83% of patients who had developed a systemic lytic state had
reperfused whereas none of the patients without such a lytic state
reopened their occluded arteries. Unlike reperfusion itself the failure to
develop a lytic state is associated with high IgG anti-streptokinase
antibodies (Hoffmann et al, 1988). The correlation coefficient between
these two parameters indicates that antibody levels only account for
25% of the variance in the develoment of a lytic state and therefore
other factors are presumably important and might include the interaction
of streptokinase with the complement pathways. It is certainly more
difficult to link complement activation by plasmin to non-reperfusion.
Perhaps full complement activation produces peptides that inhibit the
action of plasmin on fibrin and fibrinogen. Separate from the interactions
between streptokinase and the plasma proteins it is clear that plaque
morphology influences the chances of successful reperfusion.
Richardson et al (1989) reported that failed clot lysis was more likely if
the culprit plaque was complex (with evidence of a deep fissure,
intraplaque haemorrhage or a dissection of the arterial media). Similarly,
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Mattfeldt et al (1984) found that all 4 patients that failed to reperfuse in
their post mortem study had complex coronary artery lesions.
Neutrophil activation as indicated by elevation of plasma neutrophil
elastase concentrations is not evident in the early hours after infarction
prior to streptokinase therapy. This is perhaps surprising as other
workers have shown evidence of neutrophil activation in acute coronary
syndromes, unstable angina and early after acute myocardial infarction.
Mehta et al (1989) found that neutrophils from such patients exhibited
spontaneous pseudopod formation and granule extrusion. In addition the
ability of these cells to produce leukotriene B4 and to exhibit chemotaxis
was decreased suggesting previous in vivo activation. Lastly, peptide
BG, a product of elastase mediated degradation by elastase was
increased in these subjects, even within 1 hour of onset of chest pain.
In a later study Dinerman et al (1990) found that peptide Bft levels were
highest on admission to hospital and decreased over the following 16
hours. Nash et al (1989) employed white cell filterability, another
measure of activation, which was impaired 24 hours after the onset of
chest pain and deteriorated further over the ensuing 48 hours.
According to this index, neutrophil activation had returned to normal by
the 10th day post infarction. Both the study presented in chapter 3 and
the work of Bell et al (1990) found elevated concentrations of plasma
neutrophil elastase over the 48 hours after the onset of chest pain.
However neither study focused on the early hours after presentation.
The mean time to thrombolysis in patients studied in this chapter was
less than 4 hours. The most likely explanation for the differences
between these reports is that neutrophils may progress from mild
activation, both before and early after infarction, to more intense
tZH
activation over the following 24-48 hours. The variation in the reported
time course of activation reflects the variety of different indices
employed.
Neutrophil activation was modulated by streptokinase and was most
marked in the patients that did not reperfuse. The rise in elastase levels
was seen very early after starting the infusion, being apparent even in
the 20 minute sample. This neutrophil response was very similar to that
seen in the measures of complement activity and it seems likely that it is
related to plasmin generated complement anaphylotoxins. There was a
non significant positive correlation between the levels of C4a and
plasma neutrophil elastase (r = 0.41). A different time course of elastase
release was evident in the patients who reperfused. The rise in elastase
levels was less marked and was delayed occurring around the time
when reperfusion might be happening. One interpretation is that
reperfusion might be responsible for this rise. Ranjadaylan et al (1991)
also found an increase in elastase levels 1 hour after streptokinase
therapy but despite having angiographic data they do not comment on
the response of those without reperfusion. In contrast to the results of
chapter 3 and Bell et al (1990), Ranjadaylan's group reported that
elastase levels had reverted to normal 6 hours after the infusion. This
discrepancy is difficult to resolve as all three studies measured plasma
neutrophil elastase. The data in this chapter does explain the large
standard deviation seen in the elastase concentrations in the early time
points in chapter 3 and in the thrombolysed group in the study of Bell et
al (1990). It is likely to be due to excessive neutrophil elastase release in
a proportion of the patients that do not reperfuse after streptokinase.
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There was no evidence of a change in free radical activity during or after
streptokinase infusion using either the diene molar ratio or plasma
vitamin C levels as indices. This result differs from that of Davies et al
(1990a) who reported increased concentrations of malondialdehyde 2
hours after streptokinase in those with angiographic confirmation of
reperfusion. Unfortunately this marker of free radical activity is not
specific and may mirror other reactions (Knight et al, 1988). Davies et al
also measured the diene molar ratio and were unable to detect an
increase in relation to reperfusion. In this respect their data confirms the
result reported here. In contrast to both studies Grech et al (1992)
found elevated diene molar ratios within 10 minutes of successful
primary angioplasty in patients with acute myocardial infarction and no
rise in malondialdehyde over the first 48 hours. An animal study showed
similar findings with the coronary sinus concentration of 18:2(9,11)
rising on reperfusion after 90 minutes of ischaemia (Arroyo et al, 1987).
In a recent study in man Purvis et al (1992) reported a significant
increase in malondialdehyde concentration and a decrease in plasma
vitamin E concentration 90 minutes after starting alteplase (rt-PA)
therapy in those who regained artery patency. The use of two different
indicators of free radical activity improves the confidence in this result.
Despite all these studies the relationship between reperfusion and free
radicals remains confusing in man.
It is possible that free radical activity may not be particularly prominent
after reperfusion in man. This may be secondary to differences in the
rate of reflow between the clinical and laboratory setting. In most
experiments reperfusion is sudden whereas in man it is likely to be
gradual or even intermittent. This is indirectly illustrated in work by
m
Krucoff et al (1986) that demonstrated that although ST elevation falls
rapidly after successful thrombolysis, it still takes 55 minutes to reach a
steady state. Experimental studies in dogs have shown that gradual or
"gentle" reperfusion as opposed to sudden total relief of an occlusion
reduces post ischaemic damage after cardiopulmonary bypass (Okamoto
et al, 1986). Coronary angioplasty with balloon inflation for 60 seconds
provides the closest human example of sudden reperfusion after
ischaemia. Indeed one group has reported increased levels of free radical
activity in the great cardiac vein one minute after ballon deflation
(Roberts et al, 1990). Unfortunately this study can be criticised as free
radical activity was only quantified by measuring malondialdehyde
concentrations. The ischaemic insult of cardiopulmonary bypass has also
been investigated as a stimulus for free radical damage during
reperfusion in man. Davies et al (1990b) demonstrated that both
malondialdehyde and conjugated dienes were produced after reperfusion
but the site of generation was not the myocardium. Instead these free
radical markers were derived from the extracardiac tissues. Once again
this study illustrates the difficulty in establishing a pathological role for
free radicals in the heart in man.
It is interesting that the group that did not reperfuse tended to have
higher vitamin C levels and lower diene molar ratios. This may reflect a
higher background free radical activity in those that reperfuse. One
might speculate that those who went on to reperfuse might have
undergone a series of spontaneous occlusion-reperfusion cycles prior to
the final occlusion that caused admission. This might result in repeated
low grade free radical activation and cause these diffences.
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It was not a purpose of this study to establish whether the observed
inflammatory changes were beneficial or detrimental. This issue has
been addressed in a number of laboratory studies reviewed in the
introduction. Depletion of complement activity might help reduce infarct
size in the same fashion as that observed after treatment of laboratory
animals with cobra venom factor (Maroko et al, 1978; Crawford et al,
1988) or soluble inhibitory protein CR1 (Weisman et al, 1990).
Unfortunately complement depletion was only seen in those that did not
reperfuse and was associated with striking neutrophil activation which is
likely to act in the opposite direction. Indeed the beneficial effects of
neutrophil depletion in animal models of infarction have been reviewed
in the introduction. The neutrophil activation occurring in those patients
without reperfusion may increase infarct size in those with a poorer
prognosis.
In conclusion this study shows significant complement and neutrophil
activation early after thrombolysis in those without reperfusion. This is
most likely to be independent of anti-streptokinase antibodies. There
was some evidence of a modest increase in neutrophil activation in
relation to reperfusion. The marked inflammatory activation seen in
those patients without reperfusion may be harmful in the early hours
after infarction. There is little to support the view that reperfusion
enhances the inflammatory response.
Ill
CHAPTER 5
ASSESSMENT OF THE IMPACT OF
THROMBOLYSIS ON THE PRESENTATION AND





Thrombolytic therapy is not universally beneficial to all patients. Indeed
the data from the last chapter would suggest that it may cause
detrimental inflammatory activation in some patients. It has been
suggested that thrombolysis may influence or modify the pathogenesis
of ventricular septal rupture and other forms of cardiac rupture
complicating acute myocardial infarction. Reperfusion can result in a
haemorrhagic infarct (Higginson et al, 1982; Waller et al, 1987) and
dissection of blood between myocyte bundles might lead to an increased
incidence of ventricular septal rupture (Honan et al, 1990) (figure 20).
On the other hand there is evidence from autopsy studies in the pre
thrombolysis era that ventricular septal rupture follows extreme infarct
expansion (ventricular remodelling) with side to side slippage of myocyte
bundles, progressive thinning and ultimate disruption of the
interventricular septum (Weisman et al, 1988; Schuster et al, 1979)
(figure 20). Since thrombolysis decreases ventricular remodelling and
reduces infarct size (Touchstone et al, 1989; Lavie et al, 1990) it might
also decrease the incidence of septal rupture. Indeed in chapter 2 of this
thesis we saw that there was little evidence of ventricular dilatation in a
group of patients largely treated with thrombolysis.
Analysis of autopsy data from the GISSI study suggested that
streptokinase treatment might increase the risk of cardiac rupture
particularly if thrombolysis was delayed until more than 5 hours after
the onset of chest pain (Mauri et al, 1987; Honan et al, 1990). Equally,
a meta-analysis of 4 trials of thrombolytic therapy indicated that early
thrombolysis reduced the risk of cardiac rupture, but that delayed





SEVERE NECROSIS INTRAMYOCARDIAL HAEMORRHAGE
INFARCT EXPANSION DISSECTION BETWEEN BUNDLES
Figure 20 This diagram shows the postulated pathogenetic mechanisms
that may underlie the development of ventricular septal rupture. There is
good evidence from the pre thrombolysis era that severe necrosis with
infarct expansion predisposes to this complication. It is possible that
thrombolysis may also cause cardiac rupture through secondary
intramyocardial haemorrhage that disrupts the myocardium by dissecting
between the myocyte bundles
Unfortunately these large studies lack detailed information from
individual patients and in particular whether thrombolysis was
successful in these subjects. This chapter therefore comprises a review
of all cases of ventricular septal rupture over a 7 year period (1985-91)
when thrombolysis was used in the Royal Infirmary of Edinburgh. By
comparing those that did and did not receive thrombolytic therapy it
has been possible to assess changes in the presentation of this
complication resulting from this therapy.
METHODS
Identification of Cases
All discharge summaries from the Coronary Care Unit were reviewed for
patients admitted between January 1985 and December 1991. In
addition, a computer search of the discharge diagnoses of all the
patients admitted to the Royal Infirmary of Edinburgh between these
dates was performed by the Medical Records Department in the Royal
Infirmary and the Information and Statistics Division of the Common
Services Agency of the Scottish Health Service. Fifty six cases of
ventricular septal rupture post infarction were identified. The diagnosis
had been confirmed by appropriate investigation (echocardiogram, R
heart catheter or left ventricular angiography) in all cases.
Selection of control group
Forty six patients with acute myocardial infarction uncomplicated by
ventricular septal rupture, but who had received thrombolytic therapy,
were selected to match the two study groups with respect to age, sex,
site of infarction and initial ST elevation.
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Electrocardiogram Analysis
There is considerable evidence that reperfusion modifies the extent of
ST elevation on a surface electrocardiogram (Hogg et al, 1988; Saran et
al, 1990; Bren et al, 1987). Serial ST segment changes were therefore
analysed in all available electrocardiograms to assess indirectly
spontaneous or thrombolytic reperfusion. The extent of ST elevation
was measured 0.08s after the J point in the lead with the maximum ST
elevation on the initial electrocardiogram. This analysis was not possible
in 5 of the 56 patients with septal rupture, because electrocardiograms
were inadequate or missing. The mean difference between repeated
measures of ST elevation was 0.5mm (coefficient of variation 23%).
Analysis of Coronary Angiograms
Twenty nine of the 56 cases had undergone coronary angiography. All
cine films were reviewed by a single blinded observer (ADH) and the
extent of significant coronary disease (defined as a stenosis > 50%)
was assessed. Perfusion of the infarct related artery was quantified
according to the established TIMI criteria (Chesebro et al, 1987). A
score of O representing no perfusion and 3 indicating normal perfusion.
In addition the presence of perfusion by collateral vessels was noted and
graded as either poor or good if present.
Statistics
The Mann Whitney U test was used to compare continuous variables
and to assess the significance of the delayed increase in ST segment
elevation after 24 hours. Differences in the frequencies of baseline
characteristics were tested by chi square analysis. Analysis of
covariance was employed to assess significance of differences between
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the groups in ST elevation 18 hours after the onset of pain ( nadir of ST
elevation) while correcting for differences in the time of presentation
and the extent of initial ST elevation. If several ECGs were available
from an individual patient from within the same time interval the data
was averaged so that no patient was represented more than once in any
time interval. All tests were performed using the Minitab package
(release 6.1, PA, USA). A p value less than 0.05 was deemed to be
significant.
RESULTS
Baseline Characteristics (Table 5.1)
Forty two patients, who had not received thrombolytic agents, suffered
ventricular septal rupture after myocardial infarction and fourteen
patients had this complication after thrombolysis. The groups had
similar mean age, site of infarction and peak plasma creatine kinase.
Their previous medical history was also similar with respect to
hypertension and diabetes, but the thrombolysis group had a
significantly higher percentage of patients who had previously had
clinical ischaemic heart disease. A sizeable proportion of cases had
been exposed to non steroidal anti-inflammatory agents (excluding low
dose aspirin) or oral steroid prior to septal rupture (overall 36%),
although the proportions were not different in the two groups with
septal rupture. The control group tended to have fewer patients
receiving these agents (24%). The time between onset of chest pain
and ventricular septal rupture did not differ significantly between the
two study groups. In addition timing of thrombolysis was similar in the
thrombolysis group with septal rupture and the control group.
TABLE 5.1
BASELINE CHARACTERISTICS
No Thrombolysis Thrombolysis Control












65 ± 1 2
25:20
Peak Creatine
Kinase (u/l) 2210± 1801 1963 ± 1058 1464 ±1076
Previous IHD 13 (31%) 9 (64%) 19 (41%)
Previous
hypertension 16 (38%) 3 (21%) 12 (26%)
Previous
diabetes 6 (14%) 2 (14%) 3 (7%)
Anti-inflammatory
Medication 16 (38%) 4 (28%) 11 (24%)
Time to
Thrombolysis (hr) 4.2 ± 3.3 4.4± 2.2
Time to Septal
Rupture (Days) 5.1 ±4.1 3.6 ± 2.9
Footnote
1. IHD = Ischaemic heart disease (angina or infarction)
2. Anti-inflammatory medication includes non steroidal anti¬
inflammatory agents and oral steroids given either prior to myocardial
infarct and between infarction and septal rupture. (Low dose aspirin
excluded)
3. Continuous variables presented as mean ± SD
4. * represents p<0.05.
Coronary Angiography Findings (Table 5.2)
Twenty nine patients were investigated by coronary angiography as an
assessment with a view to cardiac sugery. The infarct related artery
was occluded in 80% of cases. The distribution of TIMI scores was
similar between the two groups and in no patient was perfusion normal.
Visible collateral vessels were absent in the majority of cases (80%). In
a small number collateral vessels allowed limited filling of the distal part
of the occluded vessel and in only one case did retrograde flow result in
complete filling of the blocked artery. There was a preponderance of
multivessel disease in both groups.
Serial Electrocardiogram Analysis (Figure 21)
ST elevation in electrocardiograms recorded between 0 and 4 hours
after the onset of chest pain was similar in the two groups with septal
rupture and in the control group. In addition the fall in ST segment
elevation with time after the onset of chest pain was similar in the two
groups with septal rupture and in both ST elevation tended to increase
around the time of rupture. However on formal testing the extent of ST
elevation at 72 hours was not significantly greater than that at 24
hours in any group. The control group showed a different response to
the other two groups with a rapid fall to a nadir at 1 8 hours and no
tendency to a secondary increase in ST elevation. This difference was
shown by analysis of covariance of the ST elevation at 18 hours while
correcting for differences in the initial time of presentation and the initial
ST elevation (thrombolysis with rupture vs thrombolysis without rupture,
p = 0.04; no thrombolysis with rupture vs thrombolysis without rupture,
p = 0.05).
TABLE 5.2
FINDINGS ON CORONARY ANGIOGRAPHY
(Number of Patients in Each Category)
No Thrombolysis Thrombolysis
n = 21 n = 8
Infarct artery






Poor filling 4 0
Good filling 1 0






VSD: No "011 VSD: -V- No VSD:
Thrombolysis Thrombolysis Thrombolysis
Figure 21 This figure shows the serial changes in ST segment elevation
after the onset of chest pain in 97 patients with myocardial infarction.
The circles represent data from those who developed ventricular septal
rupture (VSR) after thrombolysis (n = 14), the squares indicate the data
from patients with VSR who had not received thrombolysis (n = 37) and
the triangles reflect data from a control group who had received
thrombolysis but did not develop VSR (n = 46). The control patients
show a significantly faster reduction in ST elevation down to a lower
value and no tendency to further elevation (vs thrombolysis + VSR,
p<0.05 and vs no thrombolysis + VSR, p = 0.05). Both groups with
VSR tended to show a secondary rise in ST elevation after 24 hours.
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After Septal Rupture (Table 5.3)
The clinical diagnosis of septal rupture was confirmed in most patients
by echo and doppler cardiography (the remainder by right heart
catheterisation). Cardiac catheterisation with coronary angiography was
performed in nearly all cases that were considered for surgery. The size
of left to right shunt and the pulmonary artery pressure were similar in
both groups. The site of septal rupture was evenly distributed along the
length of the septum in the non thrombolysis group, but tended towards
the apex in the thrombolysis group.
The majority of patients were discussed with the cardiac surgeons
(82%), but only 54% underwent surgery.
DISCUSSION
This study indicates that ventricular septal rupture is associated with
persisting occlusion of the infarct related coronary artery, whether
patients have been treated with thrombolysis or not. This conclusion is
supported by the ST segment analysis, as persistent ST elevation is
associated with non reperfusion (Hogg et al, 1988; Saran et al, 1990;
Bren et al, 1987). Indeed ST elevation decreased faster and remained
less in the control group which received thrombolysis, suggesting that a
high proportion of these patients had reperfused.
There is substantial evidence that ST segment change is influenced by
reperfusion. Hogg et al (1988) found that a fall of greater than 50% in
ST elevation 2 hours after thrombolysis was 93% sensitive and 67%
specific for reperfusion. Bossaert et al (1991) also demonstrated that ST
changes are a useful marker of reperfusion as their data revealed that a
TABLE 5.3
AFTER SEPTAL RUPTURE
(Number of Patients in Each Category)
n = 42 n = 14
Investiaations
Echocardiogram 34 11
Cardiac catheter 22 8
R heart catheter 26 9
Site
Apex 12 7
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decrease in the sum of ST elevation of more than 50% over the first 2
hours after thrombolysis had a predicative accuracy for reperfusion of
88%. Conversely Saran et al (1990) reported that, when ST elevation
does not fall by at least 25% 3 hours after thrombolysis, persistent
coronary occlusion is likely (predictive accuracy 86%).
The pathological consequence of the failure of antegrade reperfusion
combined with the lack of collateral blood supply is severe and
transmural infarction. This was demonstrated in the dog model of
infarction by Reimer and Jennings (1979). Further there is now
considerable evidence that such patients are those at greatest risk of
infarct expansion with dilatation and thinning of the involved segment
(Touchstone et al, 1989; De Feyter et al, 1983; Jeremy et al, 1987).
The implication is that ventricular septal rupture even after thrombolysis
results from pronounced and rapid infarct expansion. It seems likely
that the observed secondary rise in ST segments after 24 hours
correlates with the process of infarct expansion. One can speculate that
persisting or increasing ST elevation is a result of continuing epicardial
ischaemia or reflects the side to side slippage of myocytes seen in
aneurysm formation.
Previous studies of ventricular rupture have emphasised the importance
of occlusive coronary thrombus in its pathogenesis, but all these studies
were performed in patients who had not received thrombolysis. London
and London (1965) reported 47 cases of cardiac rupture detected
amongst 1001 consecutive autopsies post myocardial infarction.
Coronary artery occlusion was evident in 76%. In a similar autopsy
study in Denmark the incidence of cornary artery occlusion was 71 % in
those with cardiac rupture (Rasmussen et al, 1979). Solberg et al (1988)
also found that occlusion by coronary thrombosis had occurred in the
majority of autopsies after cardiac rupture (74%). Both autopsy and
animal studies indicate that persisting occlusion of an artery results in a
pale infarct whereas reperfusion causes intramyocardial haemorrhage. In
a dog model of infarction 75% of the animals that underwent
reperfusion after 6 hours of ischaemia had gross evidence of
haemorrhage, in contrast to none of the non reperfused animals
(Higginson et al, 1982). In a similar study using anaesthetised dogs
Higginson et al (1983) quantified haemorrhage by measuring papillary
muscle haemoglobin. Using this technique they established that the
duration of ischaemia prior to reperfusion is important. The post
reperfusion papillary muscle haemoglobin rose from 14mg/g after 2
hours ischaemia to 28mg/g after 6 hours ischaemia and after 24 hours
was 36mg/g. In contrast the nonreperfused animals had a papillary
muscle haemoglobin concentration of 8.7mg/g. It seems likely that
haemorrhage only occurs after reperfusion in the context of ischaemic
damage to the capillary endothelium. It is relevant that streptokinase did
not increase the extent of haemorrhage seen after mechanical
reperfusion alone in an animal model of infarction (Kloner and Alker,
1984). Haemorrhage was assessed both macroscopically and by
measurement of intramyocardial haemoglobin levels. After 3 hours
occlusion and 3 hours reperfusion the control group had a myocardial
haemoglobin concentration of 26.0/g wet weight compared to the
streptokinase treated group which had a concentration of only 12.3
mg/g wet weight. Together with our data this implies that thrombolysis
does not cause septal rupture through primary intramyocardial
haemorrhage. Indeed it appears to be a failure of thrombolytic therapy
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that predisposes to the complication.
Severe haemorrhagic infarction in association with cardiac rupture after
thrombolysis has been described. Waller et al (1987) reported on 19
autopsies performed on patients after reperfusion therapy. In these
patients myocardial haemorrhage was only seen after thrombolytic
therapy and not after reperfusion induced by angioplasty alone.
Myocardial rupture was the cause of death of one of the patients in the
thrombolysis treated patients. In this case therapy had successfully
reopened the occluded artery and apparently was given within 4 hours
of the onset of chest pain. A letter in the Lancet reported 2 further
cases of patients who had died of cardiac rupture after thrombolysis
(Rodgers et al, 1990). At least the first case was in retrospect a patient
who presented with subacute cardiac rupture after an infarct 5-10 days
earlier. It seems quite possible that one explanation for the increased
incidence of cardiac rupture after thrombolysis is in fact inappropriate
administration to people with subacute cardiac rupture - a condition
which can present in a similar fashion to acute myocardial infarction,
with chest pain and ST elevation (O'Rourke, 1973).
In this series we found that 36% of cases had received anti¬
inflammatory agents prior to ventricular septal rupture compared to 24%
of patients in the control group. There is evidence from clinical and
animal studies that such treatment may cause an increased tendency to
ventricular dilatation by infarct expansion (Roberts et al, 1976;
Hammerman et al, 1983a; Boden et al, 1985). If this process is
involved in the pathogenesis of cardiac rupture then one would expect
such therapy to increase the risk. The interpretation of retrospective
studies such as this are limited as they cannot distinguish between an
adverse effect of drug therapy and such therapy being used to treat
some aspect of the process of cardiac rupture. This is relevant as non
steroid anti-inflammatory agents are used in the treatment of pericardial
pain and recurring pericarditic pain is a prominent symptom in those
who progress to cardiac rupture (Shapira et al, 1987; Dellborg et al,
1985). However, 25% of the patients (13/52) had been receiving such
therapy even prior to their acute myocardial infarction (cf 13% of
patients in the control group (6/46), NS). Although this data is not
conclusive it certainly would suggest that these drugs should be avoided
after infarction if possible.
There is no doubt that septal rupture is a serious complication and it
carries a high mortality. Indeed in this study all 26 patients who did not
have surgery died. Even with surgical intervention there is a significant
mortality and morbidity. Therapy should therefore be mainly directed at
prevention. This thesis has already discussed evidence that infarct
expansion and ventricular remodelling can be modified by vasodilator
therapy with angiotensin converting enzyme inhibitors (Pfeffer et al,
1988; Sharpe et al, 1991) and such therapy might reduce the risk of
rupture. In addition the nitrate vasodilators may be beneficial as they
have been shown to reduce infarct expansion and to increase collateral
blood flow into an ischaemic area (Jugdutt and Warnica, 1988b;
Jugdutt et al, 1981). In view of the association of cardiac rupture with
persisting arterial occlusion it would be logical that angioplasty might
reduce the incidence of cardiac rupture by permitting reperfusion in
those patients where thrombolysis was unsuccessful. This has not been
addressed in randomised trials. Perhaps the incidence of this
complication can be reduced by such interventions in high risk patients,
particularly those with persisting coronary occlusion.
In conclusion, ventricular septal rupture post infarction is associated
with persistent occlusion of the infarct related coronary artery. We have
found no evidence to suggest that effective reperfusion, and by
inference intramyocardial haemorrhage, is important in the pathogenesis
of this complication. The incidence of post infarction septal rupture






This thesis illustrates the prime importance of coronary artery
reperfusion in the prevention of left ventricular dilatation after
myocardial infarction. In the second chapter even the placebo group did
not suffer an increase in mean left ventricular dimensions between one
and five weeks after infarction. As most of the patients had received
thrombolysis, it is likely that ventricular dilatation was inhibited by the
high incidence of coronary artery patency. Conversely the data on
patients with ventricular septal rupture confirmed that persisting
coronary occlusion is detrimental. The process of ventricular rupture is
strongly associated with a failure of reperfusion, demonstrated by the
angiographic and electrocardiographic data. Ventricular septal rupture
appears to occur after severe infarct expansion, a consequence of
persisting coronary artery occlusion.
These findings are in agreement with large multicentre trials which
reported a benefit from thrombolytic therapy (GISSI-1, 1986; ISIS-2,
1988). Smaller but more detailed studies show that this advantage only
occurs in those that reperfuse. Jeremy et al (1987) found that patients
with reperfusion did not exhibit ventricular dilatation following
myocardial infarction whereas those with persisting occlusion and an
absence of collateral blood supply suffered ventricular enlargement over
the first 4 weeks.
Another way to reduce the risk of dilatation may be by using
vasodilators after acute myocardial infarction. The data from chapter 2
indicated a clinical benefit from early oral vasodilator therapy. Captopril
therapy significantly reduced the number of patients either dying or
suffering from cardiogenic shock. Such patients are likely to include
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those with persisting occlusion of the infarct related artery and those
with a large volume of infarcted muscle. However the study failed to
show any objective benefit in ventricular size or function in those
treated with vasodilator drugs and therefore treatment does not appear
to be beneficial to all patients. It is relevant that other trials of
vasodilator therapy post infarction have shown a decrease in ventricular
enlargement, but only those that selected patients who were at
increased risk of dilatation (Sharpe et al, 1991; Pfeffer et al, 1988;
Oldroyd et al, 1991). Sharpe et al (1991) selected patients with Q wave
infarction. Pfeffer et al (1988) studied patients with anterior infarction
who had ejection fractions less than 45%. Oldroyd et al (1991)
randomised cases of acute infarction who had not received thrombolysis
and had a high Norris score.
In contrast to these reports enalapril therapy did not result in a reduction
in the 180 day mortality in the CONSENSUS II study (Swedberg et al,
1992). This may reflect the lack of patient selection prior to inclusion in
the study and the possible adverse consequences of early hypotension
following intravenous enalaprilat therapy. However in the multicentre
SAVE (Survival and Ventricular Enlargement) study captopril therapy
proved beneficial (Pfeffer et al, 1992). Subjects with an ejection fraction
less than 40% were randomised to treatment with captopril or placebo
starting between 3 and 16 days following infarction (mean 11 days).
The trial protocol was very careful to exclude patients with evidence of
ischaemia (either clinical or on stress testing) and accordingly this
selection process may have reduced the number of patients recruited
with successful reperfusion. The follow up period was up to 5 years. In
this large study captopril reduced mortality, episodes of heart failure and
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recurrent infarction. Although the benefit appeared to be independent of
ejection fraction, treatment by thrombolysis or Killip class, the study
population was still selected to have impaired ventricular function
(ejection fraction <40%) and no ischaemia. It is perhaps important that
this study only used oral therapy and unlike the CONSENSUS II trial
vasodilator therapy was not started early (< 24 hours) when patients
are potentially haemodynamically unstable.
Despite the failure of CONSENSUS II to show a benefit, there may still
be a role for intravenous vasodilator therapy early after myocardial
infarction. Jugdutt and Warnica (1 988b) demonstrated that infarct size
and expansion was decreased by careful intravenous nitroglycerin
therapy avoiding excessive hypotension. Perhaps the proper role for
vasodilator therapy will be in patients who have failed to reperfuse. It is
still not certain which patients should receive this treatment post
infarction and the vasodilator's optimal timing and the best route of
administration remain to be defined.
Part of the rationale for the very early introduction of vasodilator therapy
was the putative effects of such drugs on infarct size and the acute
inflammatory response. The data from chapter 3 indicates that the
inflammatory response is not modulated by early oral vasodilator therapy
and infarct size is not significantly reduced. The lack of such 'early'
effects and the more certain benefit observed when captopril is
introduced later after infarction, when haemodynamic stability has been
achieved argue for a period of delay prior to initiating vasodilator therapy
with an angiotensin converting enzyme inhibitor.
By increasing the proportion of patients with successful reperfusion of
the infarct related artery it might be possible to inhibit or even prevent
ventricular dilatation after infarction. This might be achieved either
pharmacologically by more effective thrombolytic agents or mechanically
by transluminal coronary angioplasty. The pharmacological approach is
illustrated by the work of Neuhaus et al (1992) who demonstrated that
a 'front loaded' rt-PA regime (15mg bolus, 50mg in the first hour and
35mg in the second hour) resulted in an improved patency rate of
84.4% at 90 minutes (cf 70.3% for anistreplase (APSAC) in the same
study). Mechanical reperfusion by primary angioplasty is also capable of
reopening acute coronary occlusions. O'Keefe et al (1989) reported a
series of 500 patients in whom primary angioplasty was attempted and
in 94% of cases was successful. Another series found that primary
angioplasty attained arterial patency in 91% of patients and was
associated with an in-hospital mortality of only 5.6% (Kahn et al, 1990).
Trials comparing primary angioplasty to thrombolytic therapy are
underway but the results are not yet available in full. Zijlstra et al (1991)
reported the preliminary data from one such trial. Of twenty nine
patients randomised to streptokinase only 69% had a patent infarct
related artery at angiography. In contrast balloon dilatation was
successful in all 27 patients in the angioplasty group. Perhaps as a
result of vessel patency the pre discharge ejection fraction was
significantly greater in the angioplasty group (52% vs 45%, p<0.05).
Repeat angiography 2-3 months after the initial admission showed
vessel patency was maintained in 94% of the patients treated with
angioplasty.
The arguement for an aggressive approach to restoration of coronary
tw
artery patency is strengthened by studies of acute revascularisation in
cardiogenic shock. Moosvi et al (1992) recently reported a retrospective
analysis of 81 patients with cardiogenic shock. Although patients were
not randomised, they were selected for inclusion in the analysis using
stringent clinical and haemodynamic criteria. Patients revascularised by
angioplasty or surgery had a significantly better outcome in comparison
to those without revascularisation (50% vs 2% survived to follow up -
mean 21 months). However caution should be exercised in interpretation
of this data as it was collected retrospectively. Properly conducted
randomised studies are still awaited although some people believe such
a protocol would not be ethical.
Even if primary angioplasty were shown to be the treatment of choice in
acute myocardial infarction, present management might not be changed
appreciably. The majority of patients are admitted to hospitals without
facilties for acute angioplasty and accordingly thrombolysis is likely to
remain the most appropriate therapy for inducing reperfusion. In addition
health economics may preclude primary angioplasty even in centres
where the technique is feasible.
Prospective trials have shown that routine angioplasty is not
advantageous in all patients after thrombolysis. However there is a lack
of information on the role of angioplasty in patients that do not
reperfuse in response to thrombolytic therapy. The timing of angioplasty
in relation to the administration of a thrombolytic agent may be of
critical importance. In a paper by Beauchamp et al (1990) patients
treated with thrombolysis and angioplasty within 24 hours had an in-
hospital mortality of 15.6% in comparison to a mortality of 1.6% if the
ISi
angioplasty was delayed more than 24 hours (but less than 4 days).
The role of angioplasty may be for selected patients who have
contraindications for thrombolytic therapy or appear to have failed to
reperfuse. As yet ECG analysis is the most promising method that has
been employed to detect such patients non invasively (Hogg et al,
1988; Saran et al, 1990).
Thrombolytic therapy is not without adverse sequelae. The most
dramatic are the haemorrhagic complications. Most of the large studies
of thrombolytic therapy have shown a small but significant increased
risk of bleeding. For instance in the GISSI I study (1986) 0.3% of
patients randomised to streptokinase suffered 'major bleeds' in contrast
to none in the placebo group. This is also illustrated by the discussion in
chapter 5. It seems likely that the inappropriate administration of
thrombolytic agents to patients with partial cardiac rupture and chest
pain is one reason for the increased incidence of cardiac rupture
reported in some large multicentre trials when thrombolytic therapy was
administered later after the onset of chest pain. The retrospective
review reported in chapter 5 did not demonstrate any relationship
between reperfusion by thrombolysis and rupture of the interventricular
septum. Rupture probably does not result from intramyocardial
haemorrhage that commonly follows reperfusion.
Chapter 4 illustrates another potentially adverse effect of streptokinase.
Significant complement and neutrophil activation occurring in patients
without reperfusion may increase the extent of necrosis. The observed
pattern of complement activation suggests that the direct action of
plasmin on the complement factors is the most likely trigger for this
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response. There is no evidence to support an antigen-antibody mediated
reaction and this may partly explain the lack of correlation between anti-
streptokinase antibody titres and successful reperfusion. Hovyever
further research is required to elucidate the full mechanism and this
might in turn lead to therapy to block excessive activation. It is
interesting that even an infusion of tissue plasminogen activator is
associated with significant anaphylatoxin release (Bennett et al, 1987).
It seems unlikely that primary angioplasty will be associated with a
similar degree of acute inflammatory activation and this may be an
advantage of primary balloon dilatation over thrombolysis.
The link between myocardial necrosis and neutrophil activation is borne
out in both chapters 2 and 3 of the thesis. The question of adjuvant
therapy to modulate neutrophil or complement function remains
theoretical but at least the experimental data is promising. Perhaps the
most likely agent to be tried in man is the complement blocking, soluble
inhibitory protein (CR1) which reduced infarct size by 44% in a rat
model of infarction (Weisman et al, 1990). Careful clinical trials are
required to ensure benefit and no tendency to impaired healing and scar
formation. Complement activation by thrombolytic agents appears to
occur as a result of plasmin generation. Studies are required to clarify
whether anaphylotoxin release and the resulting neutrophil activation
are in fact clinically harmful. Free radical activity is evident in the later
period after myocardial infarction as shown in chapter 3. However this
activity does not appear to be related to reperfusion, at least using the
free radical markers that were employed in chapter 4. The role of free
radical damage in acute myocardial infarction in man remains confusing
and this is perhaps a result of difficulty in detecting these reactive
erg
molecules and in proving their involvement in tissue injury in man.
In conclusion, the restoration of coronary artery patency is of primary
importance after acute myocardial infarction and at present thrombolytic
therapy remains the appropriate treatment for most patients. Published
work does suggest a role for angioplasty, but this remains to be defined.
Oral vasodilator therapy is beneficial after infarction but perhaps only to
selected patients and only after haemodynamic stability is achieved. The
acute inflammatory response is activated in myocardial infarction and
may be excessively stimulated in some patients treated by thrombolytic
therapy with streptokinase. The role of drug therapy to modify such a
response in man should be tested, but with caution.
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